Stockwinners Market Radar for March 01, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:42 EST SCVX Corp. transfers listing to NYSE American - SCVX Corp "announced that it will transfer its listing from the New York Stock Exchange to the NYSE American. The company's decision to transfer to the NYSE American was driven by a number of factors, including more favorable thresholds for continued listing."

19:16 EST Exxon Mobil planning hydrogen production, carbon capture site in Baytown, Texas - ExxonMobil said it is planning a hydrogen production plant and one of the world's largest carbon capture and storage projects at its integrated refining and petrochemical site at Baytown, Texas, supporting efforts to reduce emissions from company operations and local industry. "Hydrogen has the potential to significantly reduce CO2 emissions in vital sectors of the economy and create valuable, lower-emissions products that support modern life," said Joe Blommaert, president of ExxonMobil Low Carbon Solutions. "By helping to activate new markets for hydrogen and carbon capture and storage, this project can play an important part in achieving America's lower-emissions aspirations." The proposed hydrogen facility would produce up to 1 billion cubic feet per day of "blue" hydrogen, which is an industry term for hydrogen produced from natural gas and supported by carbon capture and storage. The carbon capture infrastructure for this project would have the capacity to transport and store up to 10 million metric tons of CO2 per year, more than doubling ExxonMobil's current capacity.

19:04 EST Exxon Mobil halts operations at Sakhalin-1, won't make new investments in Russia - ExxonMobil issued the following statement regarding the situation in Ukraine: "ExxonMobil supports the people of Ukraine as they seek to defend their freedom and determine their own future as a nation. We deplore Russia's military action that violates the territorial integrity of Ukraine and endangers its people. We are deeply saddened by the loss of innocent lives and support the strong international response. We are fully complying with all sanctions. ExxonMobil operates the Sakhalin-1 project on behalf of an international consortium of Japanese, Indian and Russian companies. In response to recent events, we are beginning the process to discontinue operations and developing steps to exit the Sakhalin-1 venture. As operator of Sakhalin-1, we have an obligation to ensure the safety of people, protection of the environment and integrity of operations. Our role as operator goes beyond an equity investment. The process to discontinue operations will need to be carefully managed and closely coordinated with the co-venturers in order to ensure it is executed safely. Given the current situation, ExxonMobil will not invest in new developments in Russia."

18:48 EST ServiceNow COO Desai sells 5,000 common shares - In a regulatory filing, ServiceNow COO Chirantan Jitendra Desai disclosed the sale of 5,000 common shares of the company on February 28 at a price of $575.441 per share.

18:46 EST Blackstone director Porat acquires 5,000 common shares - In a regulatory filing, Blackstone director Ruth Porat disclosed the purchase of 5,000 common shares of the company on February 25 at a price of $126.21 per share.

18:39 EST Cardlytics reports Q4 MAUs up 7.2% - The company's Q4 metrics include: "Cardlytics MAUs in the quarter were 175.4M, an increase of 7.2%, compared to 163.6M in the fourth quarter of 2020. Cardlytics ARPU in the quarter was $0.49, an increase of 19.5%, compared to $0.41 in the fourth quarter of 2020. Bridg ARR was $15.3 million in the fourth quarter of 2021, compared to $12.7 million in the third quarter of 2021."

18:30 EST Boyd Gaming EVP Thompson sells 16,186 common shares - In a regulatory filing, Boyd Gaming executive VP Stephen Thompson disclosed the sale of 16,186 common shares of the company on February 25 at a price of $68.522 per share.

18:06 EST TTEC Holdings delays 10-K filing due to compilation difficulties - In a regulatory filing, TTEC Holdings said that its Form 10-K for the year ended December 31, 2021 could not be filed within the prescribed time period without unreasonable effort or expense due to difficulties in compiling and finalizing financial information and disclosures relating to a significant subsidiary, Avtex Solutions Holdings, LLC, that the Registrant acquired in the second quarter of 2021. The company intends to file the Form 10-K for the year ended December 31, 2021 prior to the end of the 15-day extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended. The company does not anticipate changes to the financial results reported in its press release issued on March 1, 2022.

17:58 EST AMC sees 2022 results heavily weighted towards second half of the year - In announcing the quarterly results, Adam Aron, Chairman and CEO of AMC Entertainment said, "AMC's fourth quarter 2021 results represent our strongest quarter in two full years, with positive Adjusted EBITDA of almost $160 million, Operating Cash Generated of more than $220 million and finishing 2021 with a record year-ending liquidity position of more than $1.8 billion. Our positive recovery glide path from the global pandemic continued in earnest in the fourth quarter. While not yet where we want to be, our progress is substantial and unmistakable. The quarter offered moviegoers a more robust and appealing film slate that culminated with the exclusive theatrical release of the now third-highest grossing movie of all-time, SPIDERMAN: NO WAY HOME, despite having been released at the height of Omicron fears. AMC took advantage of the robust fourth quarter film slate, pent-up consumer demand, and a bold advertising campaign, among other important marketing initiatives, to attract some 60 million visitors to our theatres around the world during the fourth quarter. That was a seven-fold increase over the fourth quarter of 2020, and a 50% increase compared to the third quarter of 2021." Aron concluded, "The fourth quarter of 2021 proved once again that moviegoers want to see movies in theatres. We are quite bullish that for the full calendar year of 2022 the industry box office could be nearly double that of 2021, with COVID impacts easing, with more and more major films on the docket for release, and with most major studios coalescing around an exclusive theatrical window of 45 days or more. Bookings are very strong for THE BATMAN which opens this weekend, and we have movies like TOP GUN: MAVERICK, JURASSIC WORLD DOMINION, BLACK PANTHER: WAKANDA FOREVER, AVATAR 2 and many others that will excite us all this year. We should point out, however, that the box office pacing and our results in 2022 are expected to be heavily weighted towards the second half of the year. The January and February domestic industry box office numbers are already known. While they are more than quintuple that of last year, they are nonetheless well short of pre-pandemic numbers. While no one has a perfect crystal ball, it would seem that more blockbuster activity likely will come starting in the spring and summer of 2022, continuing through yearend."

17:36 EST S&P Dow Jones says no Russian stocks to be added to indices - S&P DJI has determined that effective immediately and until further notice, no equity securities listed and/or domiciled in Russia (including ADR/GDRs) will be added to indices, even where such securities are otherwise eligible. For the avoidance of doubt, this halt on additions applies to Initial Public Offerings and Direct Listings, and to securities that meet the index-specific eligibility criteria for addition as part of a scheduled rebalancing. Similarly, S&P DJI will not delete equity securities listed and/or domiciled in Russia, even where the index-specific methodology would otherwise require this. However, this halt does not apply to security deletions that may be announced in relation to sanctions. Furthermore, for Capped Market Capitalization and Non-Market Capitalization Weighted Indices undergoing a scheduled rebalancing, S&P DJI will freeze the Additional Weight Factor for current member securities listed and/or domiciled in Russia (including ADR/GDRs) until further notice.

17:34 EST S&P Dow Jones says no Russian stocks to be added to indices - S&P DJI has determined that effective immediately and until further notice, no equity securities listed and/or domiciled in Russia (including ADR/GDRs) will be added to indices, even where such securities are otherwise eligible. For the avoidance of doubt, this halt on additions applies to Initial Public Offerings and Direct Listings, and to securities that meet the index-specific eligibility criteria for addition as part of a scheduled rebalancing. Similarly, S&P DJI will not delete equity securities listed and/or domiciled in Russia, even where the index-specific methodology would otherwise require this. However, this halt does not apply to security deletions that may be announced in relation to sanctions. Furthermore, for Capped Market Capitalization and Non-Market Capitalization Weighted Indices undergoing a scheduled rebalancing, S&P DJI will freeze the Additional Weight Factor for current member securities listed and/or domiciled in Russia (including ADR/GDRs) until further notice.

17:16 EST Finch Therapeutics pauses enrollment in PRISM4 trial - Finch Therapeutics announced that it has paused enrollment in PRISM4, its Phase 3 clinical trial of CP101 in recurrent C. difficile infection, or CDI, following receipt of a clinical hold letter from the FDA on February 24, requesting additional information about Finch's SARS-CoV-2 donor screening protocols.

17:16 EST Miromatrix Medical names Jim Douglas as new CFO - Miromatrix Medical announced the appointment of Jim Douglas as the company's new CFO effective March 1. As CFO, Jim will lead Miromatrix's finance organization and oversee all financial activities of the corporation. Douglas will succeed Brian Niebur, who will continue to serve Miromatrix as the Vice President of Finance. Douglas joins the Miromatrix team with over 25 years of relevant work experience in investment banking, industry, and public accounting. Since 2005, Jim worked at Piper Sandler in the healthcare investment banking group, advising biotechnology and medical technology companies on M&A and financing transactions, as well as providing a broad range of strategic guidance.

17:15 EST Instagram debuts auto-generated captions for videos - "The company said earlier, in a tweet: "We're excited to share auto-generated captions for IG Feed videos. Adding captions makes Instagram more accessible for those in the deaf/hard-of-hearing communities. You will have the option to turn captions on (or off). Available in 17 languages, with more to come." Reference Link

17:05 EST Marten Transport increases quarterly cash dividend 50% to 6c per share - Marten Transport announced that its board of directors has declared a 50% increase in the company's regular quarterly cash dividend to 6c per share of common stock from 4c per share, beginning with the dividend payable on March 31 to stockholders of record at the close of business on March 17.

17:03 EST Scientific Games to transform into 'Light & Wonder' - Scientific Games will now do business as Light & Wonder, a game company singularly focused on creating great games and leveraging technology to enable a seamless player experience across all platforms. As part of this transformation, the company's new website featuring iGaming and land-based casino products, technology and services will now be lnw.com. This new portal to the company offers an exciting look at player favorite games, as well as platforms, systems, player account management and hardware. Light & Wonder will operate under an assumed name until a legal name change is complete in Spring 2022. At that time, the company intends to start trading under a new stock ticker it has reserved, "LNW."

17:00 EST Ross Stores up 8% at $96.94 after Q4 earnings beat

16:59 EST SoFi Technologies jumps 16% to $13.05 after Q4 results and guidance

16:58 EST First Solar drops 12% to $66.40 after FY22 revenue guidance misses estimates

16:40 EST Advantage Solutions announces CEO transition effective April 1 - Advantage Solutions announced Tanya Domier will retire as Advantage's chief executive officer and transition to the role of executive chair effective April 1. President and Chief Commercial Officer Jill Griffin will succeed Domier as Advantage's chief executive officer and will be named to the company's board of directors upon the transition. "In the executive chair role, Domier will serve on the board of directors and provide input and counsel to the CEO and Advantage leadership on company strategies," the company said. "As I near a decade term as CEO and after multiple years of succession planning with the board, it is time for me to pass the baton to the amazing next generation of leadership at Advantage to write the next chapter in this great company's story. "I'm so excited to watch the company I love - and its team of immensely talented, determined and passionate associates - grow and prosper under Jill's leadership and look forward to supporting the company in my new role as executive chair. I know I am leaving the company in better and more capable hands and am confident the best is yet to come for Advantage," Domier stated.

16:39 EST Syndax names Kate Madigan, M.D., as Chief Medical Officer - Syndax Pharmaceuticals announced the appointment of Kate Madigan, M.D., to the role of Chief Medical Officer, effective immediately. Dr. Madigan, who brings to Syndax over 20 years of clinical hematology expertise and broad experience in the design and execution of early to late-stage clinical programs across oncology and rare diseases, will lead the company's clinical development strategy. She will succeed Michael Meyers, M.D., Ph.D., who will continue with the company through June before transitioning to serve in a consulting capacity.

16:38 EST Marathon Petroleum announces 50/50 joint venture with Neste - Marathon Petroleum announced it has entered into definitive agreements to form a joint venture with Neste for Marathon's Martinez renewable fuels project. The partnership will be structured as a 50/50 joint venture with Neste expected to contribute a total of $1B, inclusive of half of the total project development costs projected through the completion of the project. MPC will continue to manage project execution and operate the facility once construction is complete. The closing of the joint venture is subject to customary closing conditions and regulatory approvals, including obtaining the necessary permits, which depend upon certification of a final Environmental Impact Report. This strategic partnership is expected to advance the current project objectives of delivering low carbon intensity fuels to support California's climate goals. MPC and Neste will leverage their complementary core competencies in the joint venture. MPC brings experience in renewable diesel facility conversion, large capital project execution, and operating expertise in the California market. Neste brings knowledge in sustainable feedstock sourcing and in renewable liquid fuels production. The joint venture reflects both partners' commitment to obtain low carbon intensity feedstocks to achieve the project objectives of providing fuels that meet the demand driven by the Low Carbon Fuel Standard.

16:34 EST Standex acquires Sensor Solutions for $9.7M in cash - Standex announced that it has acquired privately-held, Colorado-based Sensor Solutions for approximately $9.7M in cash. The transaction is being financed from Standex's existing cash balance. The company expects the acquisition to be slightly accretive to its earnings in its first year of ownership as well as additive to consolidated free cash flow. Sensor Solutions designs and manufactures customized as well as standard Hall effect and magnetic sensor products including Hall switch and latching sensors, linear and rotary sensors and specialty sensors. These products serve automotive, industrial, medical, aerospace, military and consumer electronics end markets. Sensor Solutions trailing twelve-month revenues were approximately $4.3M.

16:32 EST WV American Water receives approval of 2022 distribution charge - In an order entered on February 28, the Public Service Commission of West Virginia granted approval for West Virginia American Water's 2022 infrastructure replacement program, referred to as a Distribution System Improvement Charge. The program and its associated surcharge mechanism allow the company to receive more timely cost recovery of certain infrastructure investments deemed just, reasonable, and in the public interest, which in turn enables the company to accelerate its infrastructure replacement and reliability program. "The DSIC surcharge plays a critical role in our company's ability to address aging infrastructure by directing additional investment to areas where improvements are most needed," said Robert Burton, president of West Virginia American Water. "Since incorporating this minimal surcharge in 2017, we've significantly reduced our water main replacement rate from 400 to 100 years, and we've invested over $171 million to replace distribution system assets at an incredibly accelerated rate. This type of investment has a direct impact on quality of life for West Virginians and the future economic development of our great state." The approved DSIC, effective today, includes $32.5 million in system-wide upgrades that West Virginia American Water will make in 2022. The improvements include $18.6 million to replace or upgrade more than 30 miles of water mains; $9.2 million to replace service lines, fire hydrants, meters, and booster stations; $2.5 million to rehabilitate water storage tanks, and $2.2 million for post-acquisition investment in troubled water systems. Accordingly, customers will pay a 1.62 percent surcharge on their monthly bills, or approximately $1.01 for the average residential customer using 3,100 gallons per month, to help fund these projects. The 2022 surcharge is a reduction on customer bills from the 2021 average residential DSIC surcharge which was about $3.55 per month. Most customers will see a prorated amount on their next bill, depending on their meter reading and billing schedule.

16:25 EST DexCom says FDA grants breakthrough device designation for DexCom CGM use - DexCom, Inc. announced the FDA has granted Breakthrough Device Designation for Dexcom CGM use in the hospital setting. Dexcom CGM uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device*, providing real-time glucose data without the need for fingersticks. The system also offers customizable alerts and alarms to help avoid potentially dangerous low and high blood sugar events. "In our extensive use of Dexcom CGM in our hospitals as part of exploratory studies over the last seven years, more than 800 of those patients treated during the pandemic, we have found that the device improves glucose control without any increased risk in hypoglycemia," said Athena Philis-Tsimikas, M.D., endocrinologist and corporate vice president for the Scripps Whittier Diabetes Institute in San Diego. "Breakthrough Device Designation from the FDA could be transformative for using CGM for in-patient care in hospitals."

16:25 EST Finch Therapeutics Group Inc trading halted, news pending

16:24 EST Amneal Pharmaceuticals enters U.S. biosimilars market with approval of RELEUKOTM - Amneal Pharmaceuticals "announced the U.S. Food and Drug Administration approval of the Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen(R). The product will be marketed under the proprietary name RELEUKO. RELEUKO was developed in collaboration with Kashiv Biosciences, LLC located in Chicago, Illinois. It is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy. Amneal expects to launch RELEUKOTM in the third quarter of 2022, along with a full patient support program. The Company is planning for a pegfilgrastim biosimilar referencing Neulasta(R) and a bevacizumab biosimilar referencing Avastin(R) to launch in 2022. Both are being reviewed by the FDA."

16:23 EST Hess sees Q1 net production 270K-275K boe/d - The company provided an update on its first quarter and full year guidance for production and cash costs and reaffirmed its fourth quarter 2022 production guidance. For the first quarter, Bakken net production is now expected to average approximately 150,000 barrels of oil equivalent per day, compared with the previous guidance range of 155,000 to 160,000 barrels of oil equivalent per day, primarily due to severe winter weather and higher natural gas liquids prices that will increase the company's earnings and cash flow but lower production entitlements under the company's Percentage of Proceeds contracts. Bakken net production for full year 2022 is now expected to be in the range of 160,000 to 165,000 barrels of oil equivalent per day, compared with the previous guidance range of 165,000 to 170,000 barrels of oil equivalent per day. The company reaffirmed its previous Bakken net production guidance range for the fourth quarter of 175,000 to 180,000 barrels of oil equivalent per day. Companywide net production for the first quarter is now expected to be in the range of 270,000 to 275,000 barrels of oil equivalent per day excluding Libya, compared with the previous guidance range of 275,000 to 285,000 barrels of oil equivalent per day, due to lower Bakken production. Companywide net production for the full year is now expected to be in the range of 325,000 to 330,000 barrels of oil equivalent per day, excluding Libya, compared with the previous guidance range of 330,000 to 340,000 barrels of oil equivalent per day, due to lower Bakken production and a delay in the startup of a third party operated tieback well at the Llano Field in the Gulf of Mexico. The company reaffirmed its previous companywide net production guidance range for the fourth quarter of 360,000 to 370,000 barrels of oil equivalent per day, excluding Libya. Cash costs for the first quarter, excluding Libya, are now expected to be in the range of $15.00 to $15.50 per barrel of oil equivalent, compared with the previous guidance range of $13.50 to $14.00 per barrel of oil equivalent, primarily due to lower production volumes as well as increased production taxes resulting from higher oil prices. Cash costs for full year 2022, excluding Libya, are now expected to be in the range of $12.50 to $13.00 per barrel of oil equivalent, compared with the previous guidance range of $11.50 to $12.50 per barrel of oil equivalent.

16:22 EST Hess raises quarterly dividend 50% to 37.5c per share - The Board of Directors of Hess Corporation declared a regular quarterly dividend of 37.5 cents per share payable on Hess Corporation Common Stock, an increase of 50% from the previously paid quarterly dividend of 25 cents per share. The dividend is payable on March 30, 2022 to stockholders of record as of the close of business on March 14, 2022. The company also announced that it had repaid the remaining $500 million of a $1 billion term loan maturing in March 2023. "The recently announced startup of the Liza Phase 2 oil development offshore Guyana has positioned the company to reduce debt and begin increasing cash returns to shareholders," CEO John Hess said. "As our portfolio becomes increasingly free cash flow positive, we plan to continue to grow the dividend and accelerate share repurchases."

16:20 EST Halliburton opens first oilfield specialty chemical facility in Saudi Arabai - Halliburton celebrated the opening of the Halliburton Chemical Reaction Plant - the first of its kind in Saudi Arabia to manufacture a broad range of chemicals for the entire oil and gas value chain as well as many other industries. The facility expands Halliburton's manufacturing footprint in the Eastern Hemisphere and strengthens and accelerates its ability to serve the chemical needs of Middle East customers. "We are excited to complete this significant investment and to deliver our chemical applications expertise to our Eastern Hemisphere customers," said Jeff Miller, chairman, president, and CEO. "This world-class plant is part of our more than $1 billion commitment to Saudi Arabia over the past ten years. It further increases our in-country presence and supports the In Kingdom Total Value Add program by providing new opportunities to local suppliers, vendors, other manufacturing partners, and the local workforce."

16:19 EST Nordstrom jumps 31% to $25.70 after Q4 results, FY22 guidance top estimates

16:17 EST Southwest Gas announces decision to separate Centuri - "We have grown Centuri into a leading, high-growth utility infrastructure services company that is uniquely positioned to benefit from the surge in infrastructure spending throughout the country. Our recent acquisition of Riggs Distler transforms Centuri by adding capabilities to support the 5G datacom buildout, offshore wind and other renewable energy transition programs. In October 2021, Riggs Distler was selected to work on a large-scale offshore wind energy project, the largest in New York to date, growing its portfolio of work in emerging clean energy technologies. Across all of our businesses, we are actively working to support the energy transition. In addition to the many opportunities at Centuri, Southwest Gas is advancing its sustainability initiatives and ongoing low-carbon projects, while MountainWest has numerous attractive opportunities with renewable natural gas, responsibly sourced natural gas, hydrogen and CO2 transportation," said ," said John Hester, President and CEO.

16:15 EST Computer Programs acquires Healthcare Resource Group - CPSI "announced that it has acquired Healthcare Resource Group. Based in Spokane, Washington, HRG is a leading provider of customized revenue cycle management solutions and consulting services that enable hospitals and clinics to improve efficiency, profitability, and patient satisfaction. Founded in 1994, HRG has approximately 400 employees, serving 77 healthcare clients, primarily located in the Pacific Northwest and Southwest, including academic medical centers, tribal organizations, and independent 200+ bed hospitals. The acquisition was consummated pursuant to a definitive purchase agreement signed on March 1, 2022, and was funded by a combination of cash on hand and additional borrowing capacity under CPSI's revolving credit facility."

16:13 EST Purple Innovation names Robert DeMartini as CEO - Paul Zepf, Chairman of the Purple Board of Directors, said, "We are very pleased to have Rob as our permanent CEO. Our search process was exhaustive, and Rob's experience, leadership, and focus on execution made him the obvious choice to lead Purple to its next phase of success. His demonstrated leadership in developing our go forward execution-oriented strategy over the past couple of months allows the company to move forward quickly."

16:11 EST Dutch Bros reports Q4 SSS up 10.1%

16:03 EST Ross Stores raises quarterly dividend by 9% to 31c per share - Dividend is payable on March 31, 2022 to stockholders of record as of March 15, 2022.

16:03 EST Ross Stores board authorizes $1.9B stock buyback - The company's Board of Directors authorized a new two-year program to repurchase up to $1.9 billion of common stock through fiscal 2023. This authorization replaces the $850 million remaining under the prior buyback authorization announced in May 2021. A total of $650 million of common stock was repurchased under the previous program in fiscal 2021.

15:41 EST Google blocking YouTube channels connected to RT and Sputnik across Europe - Kent Walker, President, Global Affairs, stated in a blog post: "The Russian invasion of Ukraine is both a tragedy and a humanitarian disaster in the making. The international community's response to this war continues to evolve and governments are imposing new sanctions and restrictions. Our teams are working around the clock to support people in Ukraine through our products, defend against cybersecurity threats, surface high-quality, reliable information and ensure the safety and security of our colleagues and their families in the region... We've launched an SOS alert on Search across Ukraine... And after consulting with multiple sources on the ground, including local authorities, we've temporarily disabled some live Google Maps features in Ukraine, including the traffic layer and information about how busy places are, to help protect the safety of local communities and their citizens. We've also added information on refugee and migrant centers in neighboring countries... While we have not seen meaningful changes in the levels of malicious activity in this region overall, our Threat Analysis Group has seen threat actors refocus their efforts on Ukrainian targets... We blocked these attempts and have not seen any compromise of Google accounts as a result of this campaign. We also automatically increased Google account security protections for people in the region and will continue to do so as cyber threats evolve... In this extraordinary crisis we are taking extraordinary measures to stop the spread of misinformation and disrupt disinformation campaigns online. Beginning today, we're blocking YouTube channels connected to RT and Sputnik across Europe. This builds on our indefinite pause of monetization of Russian state-funded media across our platforms, meaning media outlets such as RT are not allowed to monetize their content or advertise on our platforms. We have also significantly limited recommendations globally for a number of Russian state-funded media outlets across our platforms. And in the past few days, YouTube has removed hundreds of channels and thousands of videos for violating its Community Guidelines, including a number of channels engaging in coordinated deceptive practices... We are committed to complying with all sanctions requirements and we continue to monitor the latest guidance. As individuals, regions and institutions like banks are sanctioned, products like Google Pay may become unavailable in certain countries. Most of our services (like Search, Maps and YouTube) currently remain available in Russia, continuing to provide access to global information and perspectives. We will continue to monitor the situation and take additional actions as needed - and we join the international community in expressing sincere hope for a return to a peaceful and sovereign Ukraine." Reference Link

14:35 EST Sea Limited sinks after reporting Q4 results, issuing FY22 outlook - Shares of Sea Limited trading in New York are down $17.30, or 12%, to $128.30 this afternoon after the e-commerce and gaming company earlier this morning reported financial results for the fourth quarter and gave guidance for the new fiscal year. For Q4, GAAP revenue was $3.2B, up 105.7% year-on-year, gross profit of $1.3B was up 145.6% year-on-year, and total adjusted EBITDA was ($492.1M) compared to $48.7M for the fourth quarter of 2020. "With our growing scale, market leadership and strong cash balance, we believe we are well placed to increasingly leverage efficiencies across our ecosystem for growth and manage the levers of our business to reach profitability across more markets and segments in 2022 and beyond. We currently expect Shopee to achieve positive adjusted EBITDA before HQ costs allocation in Southeast Asia and Taiwan by this year and SeaMoney to achieve positive cashflow by next year. As a result, we believe that by 2025, cash generated by Shopee and SeaMoney collectively will enable these two businesses to substantially self-fund their long-term growth," said Forrest Li, Sea's Chairman and Group CEO. For the full year of 2022, Sea currently expects bookings for digital entertainment to be between $2.9B and $3.1B. "With many economies reopening further in the fourth quarter and into this year, we have observed some moderation in online activities and fluctuations in user engagement. Moreover, due to unanticipated government actions, Free Fire is currently unavailable in the Google Play and iOS app stores in India. The guidance takes into consideration these headwind factors. The midpoint of the guidance of US$3.0 billion reflects our current expectations that our bookings for 2022 will be close to the level in 2020 while also considering the uncertainty in India," the company said. Sea expects GAAP revenue for e-commerce to be between $8.9B and $9.1B, noting that the midpoint of the guidance represents an increase of 75.7% from 2021. The company expects GAAP revenue for digital financial services to be between $1.1B and $1.3B, the midpoint of which represents an increase of 155.4% from 2021.

14:03 EST Harley-Davidson suspends all shipments to Russia - Harley-Davidson, in a statement to media outlets, said: "In light of the crisis in Ukraine, Harley-Davidson has suspended its business in Russia and all shipments of its bikes to the country. Our thoughts continue for the safety of the people of Ukraine and those impacted by the crisis."

13:33 EST Lifeway Foods independent directors announce support for CEO Julie Smolyansky - Lifeway Foods issued a response to the recent 13D filing. The independent Directors of the Board issued the following response: "Lifeway's independent Directors fully supports CEO Julie Smolyansky and her continued execution of the Lifeway 2.0 strategy. Julie has consistently delivered growth for the Lifeway brands during her tenure as CEO. We believe the Company is reaching an important inflection point supported by ongoing research around probiotics and their influence on gut health, mental health and immunity, all of which are especially important with the impact of Covid-19. Her execution of the Lifeway 2.0 strategy and transition into Lifeway 3.0 has already delivered significant results for our stockholders including eight consecutive quarters of year-over-year net sales increases. Further, we believe new product innovation with the recent introduction of Lifeway Oat, a probiotic cultured oat drinkable and the recent expansion into drinkable yogurt through the acquisition of GlenOaks Farms will drive future success and we look forward to continued growth under her leadership." As fiduciaries to stockholders, the Board of Directors will consider all ideas to deliver long term value.

13:07 EST WWE expands original programming partnership with A&E - A&E and WWE announced a multi-year expansion of their programming partnership with the commissioning of more than 130 new hours of WWE-themed series and specials to air exclusively on A&E platforms and to be distributed worldwide by A+E Networks. "A&E is an amazing partner with an impressive lineup of signature series across its networks. The expansion of our partnership will allow us to continue creating a massive slate of new content with a trusted partner, while further establishing A&E as a destination for WWE fans for years to come," said Nick Khan, WWE President.

13:03 EST Dragonfly achieves Phase 1 milestone for IL-12 program with Bristol-Myers - Dragonfly Therapeutics, Inc. announced the achievement of a Phase 1 clinical development milestone for the DF6002/BMS-9896415 IL-12 program. DF6002/BMS-9896415 is a monovalent IL-12 immunoglobulin Fc fusion protein proposed to achieve strong anti-tumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive anti-tumor responses. Dragonfly received investigational new drug approval for DF6002 from the U.S. Food and Drug Administration in May 2020, and its Phase 1/2 clinical trial for patients with advanced solid tumors began in July 2020. Bristol Myers Squibb signed an exclusive worldwide license agreement with Dragonfly Therapeutics for its IL-12 investigational immunotherapy program, including its extended half-life cytokine DF6002, in August 2020. Bristol Myers Squibb intends to advance the research and development of DF6002 in oncology and hematology. Bristol Myers Squibb is responsible for the development and any subsequent commercialization of DF6002/BMS-9896415 and its related products worldwide, including strategic decisions, regulatory responsibilities, funding, and manufacturing. Dragonfly is eligible to receive additional performance-based development, regulatory and commercial milestone payments. Dragonfly will receive up to 24% royalties on worldwide net sales. "We are very encouraged by the progress being made on the DF6002/BMS-9896415 program and with Bristol Myers Squibb, whose broad range of oncology agents will help to accelerate the development of DF6002, the most advanced cytokine in Dragonfly's pipeline," said Bill Haney, Co-founder and CEO of Dragonfly Therapeutics. "We remain confident that the talent, experience and commitment to science-driven innovation of the Bristol Myers Squibb team will enable DF6002/BMS-9896415 to discover novel, life-saving solutions for patients."

12:33 EST Interactive Brokers reports February DARTs down 32% y/y - Interactive Brokers Group reported its Electronic Brokerage monthly performance metrics for February. Brokerage highlights for the month included: 2.499 million Daily Average Revenue Trades, 32% lower than prior year and 5% lower than prior month. Ending client equity of $348.5B, 6% higher than prior year and 1% lower than prior month. Ending client margin loan balances of $49.2B, 17% higher than prior year and 2% lower than prior month. Ending client credit balances of $89.2B, including $2.2B in insured bank deposit sweeps2, 5% higher than prior year and about even with prior month. 1.76 million client accounts, 39% higher than prior year and 2% higher than prior month. 319 annualized average cleared DARTs per client account. Average commission per cleared Commissionable Order of $2.51 including exchange, clearing and regulatory fees.

12:00 EST Zeta Global falls -16.1% - Zeta Global is down -16.1%, or -$2.10 to $10.91.

12:00 EST Central European Equity falls -19.7% - Central European Equity is down -19.7%, or -$2.94 to $12.00.

12:00 EST Oak Street Health rises 25.6% - Oak Street Health is up 25.6%, or $4.48 to $21.99.

11:13 EST CorePoint Lodging shareholders approve pending transaction - CorePoint Lodging announced that its stockholders voted to approve the acquisition of CorePoint by a joint venture between affiliates of Highgate and Cerberus Capital Management, L.P. The transaction is expected to close as early as March 3, subject to satisfaction of the remaining closing conditions. Keith Cline, President and CEO of CorePoint, said, "I thank our stockholders for their support of this transaction and am incredibly grateful to the CorePoint team for their continued dedication to serving our stakeholders. We look forward to completing this transaction and delivering immediate and compelling cash value to our stockholders." Under the terms of the previously announced merger agreement, upon the closing of the merger, Highgate and Cerberus will acquire all outstanding shares of CorePoint common stock in an all-cash transaction. Assuming the closing of the merger occurs on March 3, 2022, the total merger consideration to be paid upon completion of the transaction will be $15.99 per share in cash. Upon successful completion of the transaction, CorePoint's common stock will no longer be listed on the New York Stock Exchange, and the company will be privately owned.

10:45 EST Domino's Pizza: Q1 to-date comps facing 'challenging backdrop' - Labor constraints and the absence of government stimulus in 2022 as compared to last year have created a challenging backdrop to date for U.S. sales comps in Q1.

10:39 EST Starboard details Huntsman's 'significant' underperformance in presentation - Starboard Value, which identifies itself as one of the largest shareholders of Huntsman Corporation with an ownership interest of approximately 8.8% of the company's outstanding shares, announced that it has issued a presentation titled "Transforming Huntsman Corporation," outlining Starboard's views on Huntsman, the "challenges that plagued the company historically and continue to exist today," opportunities to drive improved performance, and details surrounding Starboard's slate of director nominees for election to the Huntsman board of directors at the company's upcoming 2022 annual meeting of shareholders. In its press release announcing the presentation, Starboard states: "We believe you will find our comprehensive presentation to be helpful in understanding the severity of the issues currently plaguing the company and, importantly, why we believe the election of our superior slate of nominees is required to help drive improved performance and a culture of accountability at Huntsman." Reference Link

10:18 EST Accenture, Microsoft assist Mount Sinai on transformation journey to cloud - Accenture (ACN) and Microsoft (MSFT) will assist the Mount Sinai Health System (Mount Sinai) with its transition to the cloud to help enable innovation at a much faster pace. By modernizing its infrastructure, Mount Sinai will be able to reinvest cost-savings and focus on its healthcare mission. Accenture will collaborate with New York City's largest academic medical system to help devise and securely execute its strategic cloud migration of clinical applications, including its Epic electronic health records system. Microsoft will provide quality assurance throughout this landmark academic center's Azure migration process. Accenture, together with Avanade, its joint venture with Microsoft, will help lead the development and implementation of the underlying Azure architecture on which the solution is being built. In addition, Accenture will provide hybrid cloud managed services post migration. The managed services will include around-the-clock server management and support for migrated workloads; storage and backup operations; database support; and automation and analytics.

10:17 EST Merck announces retirement of chief patient officer Julie Gerberding - Merck announced that Dr. Julie L. Gerberding, chief patient officer and executive vice president, population health and sustainability, will be retiring from Merck in May 2022. Earlier today, the Foundation for the National Institutes of Health announced that Dr. Gerberding will become CEO of the FNIH on May 16. "Julie's accomplishments during her 12 years with Merck will have an impact on our company, our communities and the patients we serve that extends well beyond her tenure with us," said Robert M. Davis, CEO and president, Merck. "Julie embraced and embodied Merck's commitment to patients and to our purpose to save and improve lives. Julie has been instrumental in developing our environmental, social and governance strategy, which will enable Merck to continue our exemplary legacy of being a force for good in the world. I am grateful to her for her leadership and for her many contributions to our company and global health."

10:01 EST Preformed Line Products Co acquires HOLPLAST, s.r.o, terms not disclosed - Preformed Line Products announced that it has acquired HOLPLAST, s.r.o., based in Prostjov, Czech Republic. "The acquisition of HOLPLAST further strengthens PLP's manufacturing capability to support the increasing global demand for our communications products. Their talented team of employees has a long history of producing high-quality molded components for a demanding customer base and will enhance PLP's existing EMEA operations," stated PLP's CEO and President Rob Ruhlman.

10:00 EST Zeta Global falls -11.6% - Zeta Global is down -11.6%, or -$1.51 to $11.50.

10:00 EST UserTesting rises 15.4% - UserTesting is up 15.4%, or $1.28 to $9.60.

10:00 EST Veritiv rises 23.2% - Veritiv is up 23.2%, or $24.82 to $131.99.

09:52 EST LivePerson jumps after Starboard discloses stake, nominates directors - Starboard Value disclosed a 9.7% stake in LivePerson, which represents over 7M shares, an increase from the 8.5% stake the firm disclosed last night. The filing with the SEC allows for activism. On February 25, Starboard delivered a letter to the company nominating a slate of director candidates, including Peter Feld, John McCormack, Vanessa Pegueros and Yael Zheng, for election to the board at the company's 2022 annual meeting of stockholders. "As evidenced by their detailed biographies below, the Nominees have backgrounds spanning information technology, marketing, operations, finance, private equity, restructuring, strategic transformation and public company governance," Starboard said in its regulatory filing. The activist added that it intends to engage in discussions with management and the board of LivePerson regarding board representation. Shares of LivePerson are up 15%, or $3.11, to $23.39 in early trading.

09:47 EST Shift4 Payments falls -9.3% - Shift4 Payments is down -9.3%, or -$4.91 to $47.74.

09:47 EST 3D Systems rises 12.0% - 3D Systems is up 12.0%, or $2.13 to $19.95.

09:47 EST Veritiv rises 17.5% - Veritiv is up 17.5%, or $18.71 to $125.88.

09:36 EST Target says growing on a bigger base than ever, opportunities are 'immense' - Says supply chain pressures working themselves out, but will still take time. Says seeing strong sales of Ulta Beauty (ULTA) products in stores. Targeting 800 Ulta Beauty locations over time. Says partnership with Levi Strauss (LEVI) continues to grow. Comments taken from Q4 earnings conference call.

09:23 EST ENGlobal expands into the Permina Basin - ENG announced that, due to the significant increase in client demand for its engineering, procurement, automation, fabrication, and construction services in the Permian basin in West Texas, the company has commenced operations there based out of Monahans, Texas. ENG's West Texas operations will utilize and support local businesses, and labor and equipment suppliers in addition to engineering and project services support from its Houston, Denver, and Tulsa offices, as well as from its well-established fabrication facilities in Henderson, Texas and its integration facilities in Houston, Texas to provide its suite of services. This will also allow the company to expand its existing client base by providing highly competitive, safe, quality engineering, procurement, construction, fabrication and integration project execution to the area. This announcement follows an aggressive automation upgrade of ENG's processes and equipment across the board in both of its fabrication and integration facilities with the objective of ensuring a focus on safety, quality and cost.

09:21 EST Tiziana's former subsidiary announces publication of data on StemPrintER - Tiziana Life Sciences' former subsidiary, AccuStem Sciences, announced publication of new data in the European Journal of Cancer. Results demonstrate that StemPrintER is highly prognostic for risk of distant recurrence in women with breast cancer. Investigators from the European Institute of Oncology, IEO, in Milan and The Royal Marsden Hospital in London evaluated 776 tumor samples from the TransATAC cohort, a subgroup of estrogen receptor positive, post-menopausal patients from the prospective, randomized ATAC trial. The TransATAC study has been used to evaluate many of the commonly used breast cancer risk scoring assays, including OncotypeDX, Prosigna, EndoPredict and Breast Cancer Index. In this analysis, investigators demonstrated that patients with a StemPrintER Risk Score, SPRS, Low result had significantly better outcomes than patients with a SPRS High result. Patients with a SPRS Low result had a 5.8% risk of distant recurrence at 10 years versus 23.2% risk of distant recurrence in patients with a SPRS High result.

09:20 EST EnWave launches REVworx, a vacuum microwave toll drying facility - EnWave announced that its vacuum-microwave toll drying facility, REVworx, is officially open for business. REVworx offers on-demand contract manufacturing services for the production of high-quality, vacuum-microwave dried snack and ingredient applications for food companies of all sizes. REVworx is the first large-scale vacuum-microwave toll processing facility in North America that is exclusively offering drying services for third-parties. The opening of the REVworx facility will open opportunities for both global and local food manufacturers to not only create new food ingredients and snacks for commercialization, but also enable growers to salvage and process imperfect produce and reduce overall food waste.

09:19 EST Matterport says app developers use digital twins to present properties - Matterport and app developers AgentRelay and Boost3D are using digital twins to change the way real estate businesses present properties for sale. Both developers use Matterport to create virtual 3D experiences for the real estate industry, enabling industry professionals to offer their clients a more immersive home buying experience.

09:17 EST Tetra Trust, Knox partner to bring crypto custody to Canada - Tetra Trust announced a strategic alliance with KNOX Capital and KNOX Industries, whereby Tetra will offer institutional clients custody services using Knox's proprietary, insurable custody system, maintained by a qualified Canadian custodian, Tetra. In addition, Tetra Trust will acquire certain assets, facilities and insurance policies currently used by Knox and provide custody services for Knox's existing Canadian customers. Tetra and Knox, two of Canada's leaders in cryptocurrency custody, will be joining forces to provide the Canadian market with a y solution offered by a "qualified custodian," under National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and as a "custodian" under National Instrument 81-102 Investment Funds. "Tetra is excited to partner with Knox as they have been a Canadian pioneer in Bitcoin custody. The institutional market for a trusted, secure custody provider for cryptocurrency continues to grow and Tetra is uniquely positioned as the first and only trust company licensed to custody digital assets to serve this growing market," said Eric Richmond, CEO of Tetra Trust. Tetra Trust is back by Coinsquare and Coinbase Ventures.

09:15 EST Daxor CEO provides corporate update in letter to shareholders - Daxor issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on February 28, 2022 from CEO & President, Michael Feldschuh. "Dear Fellow Shareholder... It is my pleasure to report on Daxor's full year results for 2021. Our net asset value has risen strongly, and the operating business is experiencing exciting growth and development - increasing revenues from commercialization, great progress in research and development for our next-generation systems set to launch this year, and a growing body of clinical evidence from leading research centers of the unique value of our diagnostic to save lives and vastly improve health and hospital economic outcomes... In 2022 Daxor plans on launching its program of new point-of-care blood volume analysis systems, developed under multiple contracts with the US Department of Defense as well as grants from the National Institutes of Health...I have written in the past that to realize that promise and the enormous market potential for our products requires the company to execute on three key areas of performance: strong commercialization, next-generation product development, and continued clinical outcomes. I am pleased to report that in 2021 we made important breakthroughs building on our focus in each of these key areas."

09:15 EST Mawson in 100MW hosting co-location pact, debt facility with Celsius Mining - Mawson Infrastructure Group announces it has signed a new hosting co-location agreement for approximately 100 megawatt and associated debt facility with Celsius Mining. Mawson expects first mining hardware under this agreement to be deployed towards the end of Q1, 2022. This brings total Luna Squares hosting co-location agreements in place to approximately 102 MW. Mawson intends to deploy the mining hardware inside its Modular Data Centre technology at its facilities in the United States. In addition to the debt facility, Mawson has issued Celsius Mining 3,850,000 warrants, exercisable for 3,850,000 in common stock at $6.50. Mawson expects Bitcoin Self-Mining to be at 3.35 EH by Q2, , and target of 5 EH online by early Q1 2023 reiterated. James Manning, CEO and Founder of Mawson, said, "We are delighted to have signed our largest hosting co-location customer to date, and look forward to working closely with Celsius Mining moving forward. The industry is experiencing a shortage of energy and energy infrastructure - having focused as a business on 'Infrastructure First' long ago, this enables us to take on strategic customers in our hosting co-location business. Demand and inbound enquiry for hosting continues to rise, and we look forward to updating stockholders on this front further in due course."

09:10 EST Emcore introduces Model 1995 1550 nm High-Power CW Source DFB Laser - EMCORE Corporation announced its new Model 1995 1550 nm High-Power Continuous Wavelength Source Distributed Feedback Laser for LiDAR and autonomous vehicle applications. The model 1995 laser is designed in a cooled TOSA form-factor in a hermetic TO56 package with 6+1 pins and is characterized for use as a Continuous Wavelength coherent optical source laser for LiDAR technology. The 1995 laser incorporates a high-isolation and high-efficiency coupling scheme to deliver 15 dBm of CW optical power with excellent spectral coherence. It expands EMCORE's product offering for LiDAR which also includes the Model 1790 1550 nm High Power CW Source Laser for LiDAR in EMCORE's classic 14-pin butterfly package.

09:09 EST Emcore introduces Model 1994 1550 nm High-Power CW Source DFB Laser - EMCORE Corporation announced its new Model 1995 1550 nm High-Power Continuous Wavelength Source Distributed Feedback Laser for LiDAR and autonomous vehicle applications. The model 1995 laser is designed in a cooled TOSA form-factor in a hermetic TO56 package with 6+1 pins and is characterized for use as a Continuous Wavelength coherent optical source laser for LiDAR technology. The 1995 laser incorporates a high-isolation and high-efficiency coupling scheme to deliver 15 dBm of CW optical power with excellent spectral coherence. It expands EMCORE's product offering for LiDAR which also includes the Model 1790 1550 nm High Power CW Source Laser for LiDAR in EMCORE's classic 14-pin butterfly package.

09:08 EST Splash Beverage Group expands distribution through Suncoast Beverage - Splash Beverage Group announced that through its existing agreement with Suncoast Beverage Sales in Southwest Florida, it will now distribute SALT tequila and TapouT performance drinks as well.

09:07 EST CleanSpark increases salaries of mining operations workers - CleanSpark announced that it has increased the starting salary of all existing entry-level positions in its mining operations to $19 per hour. The hourly pay of the Company is now more than that of similar positions at the biggest e-commerce or cloud-computing companies in the United States. "We want to attract the A-players with great pay and benefits," says Matt Schultz, Chairman at CleanSpark. "Like the biggest tech giants, we want to be known for having strong talent that gets paid well."

09:06 EST Hostess Brands outlines long-term targets ahead of investor day - Hostess Brands will outline the company's long-term strategy to deliver growth and shareholder returns at its Investors Day at noon ET. The updated financial targets as part of the new long-term growth algorithm include: organic revenue growth in the mid-single digits, adjusted EBITDA growth of 5%-7% and earnings per share growth of 7%-9%. "We believe we have built a fantastic foundation at Hostess Brands. While we are proud of our strong performance during a period of unprecedented volatility, we are even more excited about the future as we build the Company into a snacking powerhouse," said Callahan. "Today, we are introducing a new long-term growth algorithm, which targets top-tier financial performance over the long term."

09:06 EST Bassett Furniture finalizes sale of Zenith assets to J.B. Hunt - Bassett Furniture Industries (BSET) announced that it has completed the sale of substantially all of the assets of Zenith Freight Lines, LLC, a wholly-owned subsidiary of Bassett, to a wholly-owned subsidiary of J.B. Hunt Transport Services, Inc. (JBHT). As previously announced, the sale price is approximately $87 million subject to a customary post-closing working capital true-up. Bassett and J.B. Hunt have also entered into a long-term agreement whereby J.B. Hunt commits to providing Bassett with the exceptional service Zenith has performed for Bassett for almost 50 years.

09:05 EST Pulmatrix names Dr. Margaret Wasilewski as Chief Medical Officer - Pulmatrix announced the hiring of Dr. Margaret Wasilewski as the company's Chief Medical Officer effective March 1. Dr. Wasilewski leverages over 25 years of experience in pharmaceutical drug development. She led the clinical development program for treatment and recurrence prevention in Clostridioides difficile infection as Vice President Research and Development-Medical at Summit Therapeutics. Dr. Wasilewski held various leadership roles at Eli Lilly and Company, Targanta Therapeutics, and Shire. Her clinical development experience includes bacterial and viral infections, sepsis, neurology, and rare disease. As President of ID Remedies, LLC, she has provided scientific, medical, and regulatory consultation and business development to various biopharmaceutical companies.

09:03 EST CME Group to launch Micro-Sized Bitcoin and Ether options - CME Group announced it plans to launch options on Micro Bitcoin and Micro Ether futures on March 28, pending regulatory review. The new Micro Bitcoin and Micro Ether options contracts will be one-tenth of their respective underlying tokens in size and will offer a wide range of market participants - from institutions to sophisticated, active, individual traders - more ways to manage their exposure to the top two cryptocurrencies by market capitalization. These contracts will complement the existing Bitcoin options contracts, sized at five bitcoin and launched in 2020. Additionally, they will allow clients to express long- or short-term views with a choice of monthly as well as Monday, Wednesday and Friday weekly options expiries.

09:02 EST RedHill Biopharma: Phase 2 part of Phase 2/3 study of RHB-107 met endpoint - RedHill Biopharma announced top-line results from the Phase 2 part of the Phase 2/3 study of once-daily oral RHB-107 in non-hospitalized symptomatic COVID-19 patients, predominantly conducted in the U.S. as well as South Africa. Although not powered for efficacy assessment, the study showed highly promising efficacy results delivering a 100% reduction in hospitalization due to COVID-19, with zero patients on RHB-107 hospitalized with COVID-19 compared to 15% on the placebo-controlled arm requiring hospitalization. Furthermore, the study showed an 87.8% reduction in reported new severe COVID-19 symptoms, with only one patient on RHB-107 compared to 20% of patients on the placebo-controlled arm experiencing new COVID-19 related severe symptoms. The study met its primary outcome measure, demonstrating a favorable safety and tolerability profile of RHB-107. Study arms were well balanced with respect to baseline disease severity, risk factors and vaccination status. Patients were also tested for the specific viral strain, with the most common variant being Delta, found in 62.5% of the patients that had next generation sequencing. "These very promising efficacy results, achieved despite a small overall sample size, are impressive. Coupling the efficacy results with successfully meeting the primary endpoint of good safety and tolerability and convenient once-daily dosing, positions oral RHB-107 as a potential highly beneficial treatment for COVID-19 outpatients early in the course of disease in order to reduce symptom severity and prevent disease progression and hospitalization. Given the limitations of current options for early treatment of COVID-19, we are excited to progress the development of RHB-107, subject to additional discussions with regulatory authorities," said Terry F. Plasse MD, Medical Director at RedHill. "Equally important is our expectation that RHB-107, with its human cell factor targeting, would maintain its action irrespective of spike protein mutations, thus likely making it a highly desirable variant-agnostic potential treatment option."

09:02 EST NeuroSense granted key patent for ALS drug PrimeC in Australia - NeuroSense Therapeutics announced the grant of a key patent in Australia. The patent, which was already granted in the US in 2021 (US 10,980,780), is titled "Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases", and covers the company's unique fixed-dose combination of ciprofloxacin and celecoxib, two US FDA-approved drugs that are the active ingredients in PrimeC, NeuroSense's lead development candidate for treating Amyotrophic Lateral Sclerosis. This patent will last until June 2038, subject to appropriate maintenance and renewal.

08:57 EST BellRing Distribution announces commencement of senior notes offering - BellRing Distribution announced that it intends to commence a private offering to eligible purchasers of $840.0 million in aggregate principal amount of senior notes due 2030. The Notes are being offered in connection with the transactions involved with Post Holdings, anticipated spin-off of 80.1% of its interest in New BellRing to Post shareholders, and completion of the Notes offering is conditioned upon, in addition to market and certain other conditions, the substantially concurrent completion of the spin-off and the related merger of a subsidiary of New BellRing into BellRing Brands. The Notes will be issued to Post as partial consideration for the transfer by Post to New BellRing of certain assets, including all of the equity interests held by Post in BellRing, BellRing Brands, LLC and cash. Post will then transfer the Notes to certain of its lenders or their respective affiliates to satisfy outstanding Post debt owed to the lenders. New BellRing will use the cash received from Post, along with cash on hand and a draw on the new revolving credit facility that it will enter into as part of the transactions, to refinance BellRing LLC's existing indebtedness and to pay fees and expenses related to the transaction, as well as to distribute cash to existing BellRing stockholders in connection with the above-described merger. The Selling Noteholders intend to offer the Notes for resale in a transaction exempt from registration. The Selling Noteholders will receive all of the proceeds from such offering. Upon the closing of the offering, the Notes will be unsecured unsubordinated obligations of New BellRing and, fourteen days after the closing of the offering, will be guaranteed by New BellRing's existing and subsequently acquired or organized domestic subsidiaries. The Notes will not be an obligation of Post or any of Post's wholly-owned subsidiaries. The final terms and amounts of the Notes are subject to market and other conditions, and may be materially different than expectations.

08:55 EST Pinduoduo, FAO China organize webinar on smart agriculture - The Food and Agriculture Organization of the United Nations Representation in China and Pinduoduo jointly held a webinar on how smart agriculture can bolster food production and security. Representatives from FAO, Pinduoduo, China Agricultural University, Chinese Academy of Agricultural Sciences, and finalists of the Pinduoduo-organized Smart Agriculture Competition took part and presented at the webinar.

08:51 EST Neuronetics announces commercial launch of MT Cap in the US - Neuronetics announced the commercial launch of the MT Cap in the U.S. The company's nationwide team of clinical training managers and practice development managers are trained and available to support Neurostar practices with this new technique for determining a patient's Motor Threshold. "Having the MT Cap commercially available to our NeuroStar providers and their patients signifies another step towards making NeuroStar more easily adoptable by practices and their patients," said Keith Sullivan, President and CEO of Neuronetics, Inc. "The customer feedback from the exclusive limited release over the past two months has exceeded our expectations. Based upon the learnings from the limited release, we expect the MT Cap to be a critical new tool that helps streamline MT determination for every patient and simplify new customer training. This time savings, coupled with the fact that the MT Cap is included for NeuroStar customers at no additional charge, will be beneficial for current NeuroStar providers, their patients, and new providers looking to offer the treatment."

08:47 EST Applied UV expands reach into global cannabis market - Applied UV announces that its recently acquired Kes Science and Technologies acquisition continues its penetration into the Global Cannabis market. Kes recently received a large order for its AiroClean 420 from its US Distributor Growers House. Applied UV's internal research estimates that the legal cannabis industry grew 46% from 2019 to 2020 achieving revenue in excess of $17B. The cannabis crop is subject to many viruses that could impede growth and destroy crops. Powdery mildew is one of the most potent destroyers of cannabis grows in the world. The pathogen spreads through the air and gets into the vascular system of the plants. It remains hidden until two weeks into flowering before it wreaks havoc on the entire grow. When it is detected, growers must destroy the crop, remove all their equipment, and conduct an intensive and costly deep clean. Certain fungicides can combat powdery mildew, but these are illegal in some states and are of questionable safety given they are sprayed on something intended for human consumption. Kes Science's AiroClean420 eradicates powdery mildew and other airborne pathogens and not only protects the crops but helps protect the personnel from airborne pathogens working in the facilities growing them as well. Applied UV believes the Kes Science acquisition may allow Applied UV to further expand into the booming global legal cannabis market and capitalize on its rapid growth where further market penetration could result in increased market share, revenue, and earnings growth. The Kes Science & Technology Airoclean 420 Air Purification systems are currently used by numerous commercial cannabis grow operations throughout the US to help protect crops from all kinds of dangerous and contagious pathogens, including powdery mildew, grey mold/botrytis, allergens, bacteria, viruses, odors, VOC's.

08:46 EST Vyant Bio issues letter to shareholders - Vyant Bio released a Letter to Shareholders from Chief Executive Officer, Jay Roberts. "Dear Fellow Shareholders, As we enter 2022, we are beginning to see the benefits of our 2021 strategic actions to transform Vyant Bio into a pure-play drug discovery and development biotechnology company. Based on this transformation, I believe we are now well-positioned to pursue the discovery and development of repurposed and novel therapeutics to treat neurological developmental and degenerative diseases such as for Rett Syndrome, CDKL5 Deficiency Disorders, and Parkinson's Disease...We enter 2022 focused on cost efficiency and effectively bringing a repurposed drug candidate into clinical trials in the first half of 2023. Our first two novel drug candidates are expected to enter clinical trials in the second half of 2023... Further Focus and Continued Transformation: As we narrowed our focus and transformed our business strategy post-merger, we identified non-core activities and commenced taking actions to either discontinue or pause certain discovery programs and activities to allow our more promising R&D activities to take precedence and efficiently deploy our human and capital resources. We have recently engaged Colliers Securities... to assist us in the divestiture of our vivoPharm business... We expect to have this transaction completed in the first half of 2022... Further, as we noted in our September 30, 2021 Form 10-Q filing, we began transitioning certain R&D activities from our La Jolla, California location to our Maple Grove, Minnesota facility...As we refined our post-merger strategy, I have never lost sight of our shareholders and would like to thank you for your investment in Vyant Bio and express our appreciation for your ongoing support.."

08:45 EST Sparta Commercial Services announces contracts from Town of Candor - Sparta Commercial Services announces that the Town of Candor, North Carolina has again turned to Sparta to obtain the equipment their town needs. The Company has funded multiple contracts for the Town of Candor, who has utilized the Company's Municipal Finance Program 11 separate times since 2014, for a variety of essential-use equipment such as police cruisers, fire equipment, industrial vacuums, and maintenance equipment.

08:44 EST Brookfield Renewable Partners completes annual filings - Brookfield Renewable Partners and Brookfield Renewable Corporation announced today the filing of their respective 2021 annual reports, including audited financial statements for the year ended December 31, 2021, on Forms 20-F with the SEC on EDGAR as well as with Canadian securities regulatory authorities on SEDAR.

08:42 EST Allogene Therapeutics publishes inaugural ESG report - Allogene Therapeutics published its first ESG report. The report details the Company's commitment to corporate integrity and sustainable business operations and highlights its priorities: employees, the environment, and importantly, patients, and increasing their access to potential life-saving products. Highlights of the ESG report describe Allogene's commitment to: Improving Access to CAR T Therapy: Allogeneic CAR T has the potential to treat dramatically more patients, across more cancer types and at earlier stages, faster and with greater convenience than autologous CAR T therapies. Creating a Diverse and Inclusive Workplace: The Company is proud of the diversity of its workforce and strives to enable opportunity for underrepresented minorities. In 2020, the Company established a diversity, equity and inclusion Committee and policy, formalizing its commitment to DEI initiatives. Recruitment efforts are designed to attract candidates from underrepresented groups and the Company has implemented interview practices to safeguard against potential unconscious bias. Fostering a One Allogene Culture: In 2021, the Company launched One Allogene, an initiative that defines its culture and the core behaviors that will help drive development of AlloCAR T products for patients in need. One Allogene permeates throughout the Company, including through DEI initiatives, employee orientation and education, manager training, performance reviews, peer recognition, career development and wellness programs. Prioritizing Environmental Sustainability: The Company has several ongoing efforts to protect the environment, including utilizing renewable energy sources to reduce greenhouse gas emissions. The Company's state-of-the-art cell manufacturing facility, Cell Forge 1, was designed and constructed to be energy efficient and uses 100% carbon-free, renewable energy. Cell Forge 1 is expected to earn LEED Gold certification in design and operation in 2022. Pursuing the Highest Ethical Standards: In December 2021, the Company's Board of Directors, and Nominating and Corporate Governance Committee, approved an amendment to the Committee's charter for oversight of ESG matters. The Committee also has responsibility for reporting to the Board on ESG matters.

08:41 EST UPS chief information, engineering officer Juan Perez retires - UPS announced that Juan Perez, Executive Vice President and Chief Information and Engineering Officer is retiring after a distinguished career. Scott Price, Executive Vice President International, also is retiring from the company; both are effective March 31, 2022. Kate Gutmann, Chief Sales and Solutions Officer and Executive Vice President UPS Global Healthcare will move to a newly created role of Executive Vice President and President International, Healthcare and Supply Chain Solutions. Kate will be responsible for these business units, including their operations and sales teams as well as global solutions and global sales operations. Kate's current role will be eliminated as she takes on these broader responsibilities. Nando Cesarone, Executive Vice President and President U.S., including small package, transportation and the UPS Airline operations, will assume additional responsibility for U.S. sales as well as the company's automotive, and global buildings and systems engineering groups. The company has an external search underway for a new leader for the role of Executive Vice President and Chief Information Officer.

08:41 EST Domino's Pizza see 2-3 year global retail sales growth, ex-FX, 6%-10% - Sees 2-3 year global net unit growth 6%-8%.

08:39 EST Color Star Technology announces partnership with France's Galtiscopio Gatti - Color Star Technology announced that Galtiscopio Gatti, a luxury women's watch brand from France, has officially entered the Color World metaverse platform. Color Star will assist the brand in its online brand marketing and help the company seize the new market opportunities presented by the metaverse.

08:38 EST MarineMax extends previously announced stock repurchase program - MarineMax announced that its Board of Directors approved an extension of its previously announced stock repurchase plan authorizing the Company to repurchase up to a total of 10M shares of its common stock during the period ending March 31, 2024. The new repurchase plan extends the March 2020 plan, which authorized the repurchase of up to 10M shares through March 31, 2022, of which approximately 700,000 shares had been repurchased as of February 24, 2022. Under the plan, the Company may purchase common stock from time to time in the open market or in privately negotiated block purchase transactions. The amount and timing of any purchases will depend upon a number of factors, including the price and availability of the Company's stock and general market conditions. The Company intends to repurchase shares to mitigate the dilutive effect of restricted stock and shares repurchased may be reserved for later reissue in connection with employee benefit plans and other general corporate purposes.

08:37 EST L.B. Foster maintains 'optimistic outlook' regarding long-term trends - The Company's backlog continues to be robust at $210.2M, although down versus prior year and prior quarter due to lower order rates in Rail, Technologies, and Services and Steel Products and Measurement. The Company is maintaining its optimistic outlook regarding the longer-term trends in its core end markets of freight and transit rail and general infrastructure. While overall quotation activity and demand in these markets continues to improve, they are still below pre-pandemic levels. Consistent with previous expectations, midstream energy markets and related pipeline investment projects remain at depressed levels and are expected to remain so for the foreseeable future. Ongoing cost containment measures in the businesses serving these markets will be critical to minimizing further operating margin deterioration. The present inflationary environment in labor and raw materials continues to pressure margins across the business, and the Company has taken and will continue to take pricing actions where possible to help mitigate such impacts. In addition, the Company continues to take proactive steps to manage disruptions in raw materials, labor, supply chains, service partner resources, and lingering COVID-19 related effects to mitigate their adverse impact on its operations and results as much as possible. While such conditions and the related impacts are expected to improve in 2022, they could persist throughout 2022 and possibility longer.

08:36 EST Converge Technology says Portage Cybertech acquires 1CRM Systems - Converge Technology Solutions is pleased to announce its majority owned subsidiary, Portage CyberTech has acquired 1CRM Systems Corp. 1CRM is the twenty-eighth acquisition made by Converge or its affiliates and the second acquisition made by Portage CyberTech, A Converge Company. Headquartered in Victoria, Canada, 1CRM's SaaS-based software suite has been deployed to thousands of client sites across North America, Europe, and Australia. 1CRM's software operates in the cloud and on premise, with the ability to handle daily task management, marketing automation, sales and opportunities, order management, client service and project management in a single system. This acquisition delivers a key set of business management tools for clients to manage their business day, driving more value to their customers and attracting more clients to our platform. 1CRM Systems Corp. had trailing twelve-month revenue of approximately $820 thousand for the period ended October 31, 2021. The purchase price consisted of the following: $3 million in cash paid at closing; up to an aggregate of $2 million in earn-out payments for the two years following closing of the acquisition based on the achievement of certain milestones.

08:35 EST UWM Holdings sees Q1 production $33B-$42B - The company said, "We anticipate first quarter production to be in the $33-$42 billion range, with expected gain margin between 75 and 85 bps."

08:33 EST Laughing Water issues letter to board of directors, employees of Houghton - Laughing Water Capital issued a letter to the Board of Directors and employees of Houghton Mifflin Harcourt Company. In the letter, LWC explains why it will NOT be tendering its shares into Veritas Capital's $21 per share tender offer to acquire the Company. The full text of the letter follows: "Dear Members of the Board and Valued Employees: Laughing Water Capital is a significant stockholder of Houghton Mifflin Harcourt Company and has been a public cheerleader for the Company over the last year... we are extremely disappointed by the Board of Directors' decision to support a tender offer from Veritas Capital that seemingly will allow Veritas to capture the spoils that HMHC's employees have worked so hard for, and that HMHC stockholders have waited so patiently for. We do not believe that this tender offer is in the best interest of stockholders, and we do not believe it is in the best interest of employees, and we will thus NOT be tendering our shares... We further question the timing of this POTENTIAL transaction, as the deal was announced only two days before HMHC's previously scheduled Q4'21 conference call, where management would have surely provided guidance for FY'22, and provided information about the continued growth of HMHC's SaaS offerings, which clearly deserve a higher multiple than traditional education assets....We also question the price the Board chose to endorse... If HMHC specifically - or the K-12 Content Industry more broadly - was about to plummet off a cliff, then perhaps this multiple would be justifiable... We would not argue that this super-normal FCF potential should be capitalized indefinitely in the form of a drastically higher acquisition multiple, but to suggest that stockholders should sell at an extreme discount to normalized levels in advance of super-normal levels boggles the mind...In conclusion, we believe this PROPOSED transaction comes with more questions than answers as it does not appear to be in the best interest of stockholders or employees. We thus WILL NOT TENDER OUR SHARES, and we invite the Board and management to ponder the above questions internally when considering if they are fulfilling their fiduciary duties."

08:28 EST Kandy announces IPTF Click-to-Connect available to AT&T IPTF users - American Virtual Cloud Technologies' Kandy Communications business unit announced that IPTF Click-to-Connect is available to AT&T IP Toll-Free users. Together with Kandy, AT&T is helping to provide more businesses with the ability to transform their customer experience.

08:27 EST Semler Scientific: Study of QuantaFlo published in Journal of Vascular Surgery - Semler Scientific announced a study was published on-line as a pre-proof in the peer-reviewed Journal of Vascular Surgery with data collected using QuantaFlo under real-world conditions. The article is, "The Nevada Peripheral Artery Disease Screening Effort in a Medicare Advantage Population and Subsequent Mortality and Major Adverse Cardiovascular Event Riski." The study analyzed screening tests using QuantaFlo for undetected and asymptomatic peripheral arterial disease in a Medicare Advantage population with three-year follow up. In this study, 13,971 patients were tested and 31.6% had a positive result for PAD. The large metropolitan area was characterized by concentrations of atherosclerotic risk factors along with a more vulnerable socio-economic risk profile. The risk associated with detecting PAD was substantial with a 60-70% increased risk of all-cause mortality or morbidity at one year and a 40-50% increased risk of all-cause mortality or morbidity at three years. The association of risk at three years was not modified following multivariable adjustment. The study's take home message: "A positive screening result of previously undetected lower extremity PAD was independently associated with short-term and long-term increased risks for mortality and major adverse cardiovascular events in individuals aged 65 years and older living in a large, metropolitan area."

08:26 EST Domino's Pizza CEO Ritch Allison to retire, Russell Weiner to succeed - Domino's Pizza announced that Ritch Allison has informed the Board of Directors of his intention to retire from the company. Allison will continue to serve as CEO through April 30, and will remain on the Domino's Board of Directors until the company's 2022 Annual Meeting of Shareholders on April 26, 2022. The Board has appointed Russell Weiner, Domino's COO and President - Domino's U.S., to succeed Allison as the company's next CEO, effective May 1. Weiner will stand for election to the Board at the upcoming Annual Meeting of Shareholders. Allison will continue to provide his guidance and expertise to the company in an advisory capacity until he retires from Domino's on July 15. In connection with today's announcement, David Brandon will transition from Chairman of the Board to the newly established position of Executive Chairman, effective May 1.

08:24 EST Cabaletta Bio announces FDA granted FTD for MuSK-CAART - Cabaletta Bio announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, for MuSK-CAART, or muscle-specific kinase chimeric autoantibody receptor T cells, to improve activities of daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis. MuSK-CAART is being evaluated as a potential treatment for patients with MuSK-associated myasthenia gravis. Cabaletta's Investigational New Drug, IND, application was recently cleared by the FDA within the routine 30-day review period. Cabaletta plans to initiate a first-in-human clinical trial in 2022 for MuSK-CAART. "Anti-MuSK autoantibodies are observed in a subset of patients diagnosed with MG, and the limited treatment options for these patients underscore the need for a new and more effective standard of care," said David Chang, M.D., Chief Medical Officer of Cabaletta. "We believe the FDA's decision to grant Fast Track Designation highlights the need for a treatment capable of potentially delivering deep and durable responses for patients living with MuSK-associated MG. We look forward to initiating our first-in-human trial later this year."

08:23 EST FuboTV, Kantar team on advertising effectiveness to 'prove power of CTV' - Kantar, "the world's leading data-driven analytics and brand consulting company," according to a company statement, announces its partnership with fuboTV. The partnership, leveraging Kantar's flagship media effectiveness product Brand Lift Insights, allows advertisers and marketers running campaigns on fuboTV to better understand the effectiveness of their connected TV, CTV advertising and benchmark their performance against that of their competitors. We are thrilled to be partnering with Kantar to help marketers better link investments on CTV to business outcomes," said Diana Horowitz, SVP, advertising sales at fuboTV. "Marketers understand that CTV is an extremely valuable advertising medium, combining the power, reach, and the big screen experience of traditional TV with capabilities like first-party addressable audience targeting - all in a premium, brand safe environment. Now they can prove the value of CTV campaigns using Kantar's CTV insights."

08:22 EST Poet Technologies announces product demos, tech showcase event - POET Technologies announced that it will be demonstrating two advanced Optical Engine products and participating in a "Technology Showcase" event at the upcoming Optical Fiber Conference Exhibition on March 8 - 10, 2022, at the San Diego Convention Center. In addition, the Company announced the appointment of Raju Kankipati as Vice President - Product Line Management. POET's Optical Engine products will include a 200G FR4 TX (transmit) engine and a 400G FR4 RX engine which will be demonstrated live to customers, business partners, analysts, media and other attendees by appointment in its booth, #5301, at the exhibition. Interested parties are encouraged to contact the Company to arrange an appointment. Dr. Suresh Venkatesan, Chairman & CEO of POET Technologies, will also be appearing at the OFC Technology Showcase event on Wednesday, March 9, 2022, from 12:30 - 1:00 p.m. PST at the Expo Theater III and presenting a talk called "Hybrid Integration Platform for Co-packaged Photonics using POET's CMOS-based Optical Interposer". OFC is the premier event for the optoelectronics industry held in the U.S. and offers POET an opportunity to continue to grow its customer engagements and demonstrate the Optical Interposer's solutions for multiple market verticals. Additionally, the Company announced its recent appointment of Raju Kankipati to Vice President of Product Line Management. In this position, Kankipati will head up Product Management and Sales & Marketing for POET. Kankipati has more than 20 years of experience in optical transceivers, optical components, cloud data center and optical networks. Most recently he was employed at MACOM, where he was the Senior Director of Product Management for optical components, including lasers, photodetectors, silicon photonics, and photonic solutions.

08:20 EST Daseke confirms expiration of warrants - Daseke confirmed that the common stock warrants that were originally issued in 2015 in connection with its initial public offering, have expired in accordance with their terms, as of Sunday, February 27, 2022, and are no longer exercisable. NASDAQ suspended trading in the warrants on February 24, 2022, so that all outstanding trades could be settled by the expiration date. The Company had issued a total of 35,040,664 warrants. Each warrant entitled the holder to purchase one-half of one share of common stock at $5.75 per half share. Prior to the expiration date, 1,635,314 warrants were submitted for exercise, resulting in $9,403,055.50 in proceeds to the Company and 817,657 of new shares issued to the former warrant holders.

08:19 EST Popular announces entry into $400M accelerated share repurchase agreement - Popular announced that on February 28 it entered into an accelerated share repurchase agreement to repurchase an aggregate of $400M of Popular's common stock. Popular previously disclosed in a press release on January 12, 2022 its plan to repurchase up to $500M of its common stock as part of its planned capital actions for 2022. Under the terms of the ASR Agreement, on March 2 the Corporation will make an initial payment of $400M and receive an initial delivery of 3,483,942 shares of Popular's Common Stock.

08:19 EST R1 RCM issues 2021 ESG report - R1 RCM released its 2021 Environmental, Social, and Governance report, presenting its continued focus on and commitment to advancing a best-in-class ESG program. R1's 2021 ESG report and program reflects its mission to make healthcare simpler. R1 strives to achieve this by improving the patient and provider experience through innovation and technology; operating with integrity and compassion; fostering an inclusive and diverse workforce; and caring for its local and global communities and environment. These commitments, noted throughout the report with expanded narrative and metrics, support and align with leading ESG frameworks, including the United Nations Sustainable Development Goals and industry-based ESG standards recommended by the Sustainability Accounting Standards Board, and the Task Force on Climate-Related Disclosures.

08:18 EST Caladrius receives $2.3M of non-dilutive capital through NJ program - Caladrius Biosciences announced that it has received $2.3 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority. The Program enables qualifying New Jersey-based biotechnology or technology companies to sell a percentage of their New Jersey net operating losses and research and development tax credits to unrelated qualifying corporations.

08:16 EST Connect Biopharma appoints Chin Lee as CMO - Connect Biopharma (CNTB) announced the appointment of Chin Lee, MD, MPH, as Chief Medical Officer, CMO, effective March 1, 2022. Dr. Lee brings more than 15 years of clinical research and development experience in the biopharmaceutical industry. Prior to joining the Company, Dr. Lee served as Vice President, Head of Clinical Science, and Chief Medical Officer at Theravance Biopharma (TBPH).

08:15 EST F-star Therapeutics appoints James Sandy as CDO - F-star Therapeutics announced today that James Sandy has been appointed as Chief Development Officer, effective today. Mr. Sandy will lead the clinical development and advancement of F-star's pipeline. Before joining F-star Therapeutics James served as Chief Development Officer at Ellipses Pharma, Immunocore, and Creabilis Pharmaceuticals. In connection with Mr. Sandy's appointment, the company is reporting an inducement option grant under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee of the F-star Board of Directors has approved a non-qualified stock option award to purchase an aggregate of 50,000 shares of F-star common stock and 25,000 restricted stock units to Mr. Sandy. The option and RSUs were granted outside of the Company's 2019 Equity Incentive Plan as an inducement material to Mr. Sandy's acceptance of employment with the Company. The stock option will have an exercise price equal to the fair market value of F-star's common stock on his start date. The stock option vests over four years, with 25% of the award vesting on the first anniversary of his employment, and as to an additional 1/36th of the shares monthly thereafter. The RSUs vest over four years with 25% of the award vesting on the first anniversary of his employment and thereafter in equal quarterly installments over a period of three years. The vesting of both the option and the RSU is subject to Mr. Sandy's continued service through the applicable vesting dates.

08:14 EST Lipocine announces regulatory guidance on LPCN 1144 - Lipocine provided an update from the Type C guidance meeting with the U.S. FDA regarding the development path for LPCN 1144. LPCN 1144 is targeted for treatment for nonalcoholic steatohepatitis in non-cirrhotic men. NASH is a more advanced state of non-alcoholic fatty liver disease and can progress to a cirrhotic liver or liver failure, require liver transplant, and can result in hepatocellular carcinoma/liver cancer, and can lead to death. The FDA provided a written response in which it acknowledged that the New Drug Application submission of LPCN 1144 would be via 505(b)2 regulatory pathway. The FDA also agreed that no additional nonclinical studies are needed to support a 505(b)(2) NDA submission for LPCN 1144. The FDA acknowledged that in the phase 2 study completed by Lipocine to evaluate LPCN 1144 in NASH, subjects achieved improvements in key components associated with NASH histopathology after 36-weeks of treatment with LPCN 1144 in adult males. The FDA agreed that the proposed multicomponent primary surrogate endpoint is acceptable for seeking approval under the accelerated approval pathway. The FDA has recommended Lipocine either conduct a separate dose-ranging study prior to phase 3 or evaluate multiple doses in the phase 3 study. The multicomponent primary surrogate endpoint proposed to FDA by Lipocine is acceptable for seeking approval under the accelerated approval pathway and FDA recommended a phase 3 study duration of 72 weeks. The FDA has requested that Lipocine submit an updated phase 3 protocol for FDA feedback on the study design and recommended requesting an end-of-phase 2 meeting to discuss the phase 3 and confirmatory trial designs, including the plan for reading liver histopathology. "We are pleased to have achieved alignment with the FDA on key elements of a development plan for LPCN 1144 in non-cirrhotic NASH." said Dr. Mahesh Patel, Chairman, President, and CEO of Lipocine. "We plan to submit an updated phase 3 protocol to the FDA for its review."

08:12 EST Mizuho Financial Group hires Petrone as Managing Director - Mizuho Americas (MFG) announced the hiring of Anthony Petrone, CFA, as Managing Director, Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst. Petrone will be based in New York and report to Managing Director and Head of US Equity Research, Susan Gilbertson. Petrone joins Mizuho from Jefferies (JEF) where he published thematic reports on strategic, financial and emerging technology trends in the industry.

08:11 EST Workhorse Group, GreenPower Motor sign multi-year supply agreement - Workhorse Group (WKHS) and GreenPower Motor Company(GP) announced the signing of a multi-year supply agreement to facilitate the manufacturing and delivery of medium-duty Class 4 step vans into the North American market. Under the terms of the agreement, the companies have confirmed a 21-month schedule during which GreenPower will deliver 1,500 EV Star cab and chassis to Workhorse starting in July 2022. The chassis are to be used in the production of Workhorse's new Class 4 W750 step van line, which is slated to enter production in Q3 2022. Workhorse will complete the manufacturing process and deliver finished step vans to its customers in the United States and Canada. The agreement includes deposits based on delivery thresholds and also contains a renewal option. Workhorse will have exclusive rights in the U.S. and Canada to sell Class 4 step vans based on the GreenPower-supplied base vehicle. The finished Class 4 step vans will be available under the Workhorse brand with Workhorse after-sales and support service. The W750 will feature up to 150 miles of all-electric range, with a payload capacity of 5,000 lbs., as well as standard 60kW DC fast-charging and optional 60 kW wireless-charging capabilities.

08:10 EST Daxor reports NAV of $5.34 for 2021 - Daxor Corporation filed its Annual Report to Shareholders on Form N-CSR on February 28, 2022, disclosing its schedule of portfolio holdings as of December 31, 2021. Management reported a NAV of $5.24 per share for fiscal 2021 versus $3.89 for the comparable period in 2020, a $1.35 increase or 34.7%, as well as a 70.6% increase in unaudited revenues for its operating division, which produces and distributes its blood volume analysis diagnostic systems and test kits. "We are pleased with our strong financial performance for fiscal 2021 driven by a combination of sold, leased, placed devices for research, and new reference lab accounts with eleven new clients with orders to install an additional five accounts expected in Q1 of 2022. Additionally, revenue accrued from the U.S. Department of Defense orders as well as third-party companies contracting with Daxor to conduct blood volume analysis on their products has contributed to our growth," said Michael Feldschuh, CEO of Daxor. "Our operating business continues to experience exciting growth and development due to commercialization acceleration and expansion, significant progress in research and development for our next-generation systems set to launch this year, and a growing body of clinical evidence from leading research centers of the unique value of our diagnostic to save lives and vastly improve health and hospital economic outcomes." The Company also announced significant progress in its next-generation BVA technology slated for completion in the second half of 2022, funded by multiple contracts awarded by the U.S. DOD and the Center for Advancing Point of Care Technology funded by the National Institutes of Health, including a $750,000 contract for developing a novel patent-pending fluorescent tracer for use with new systems under development. The Company announced in May 2021 that two NIH-funded heart failure studies commenced at the Geisinger Medical System and with the Veterans Affair System for both inpatient & outpatient care. The Company also announced in August 2021 that a promising research letter on the use of Daxor's BVA-100 analyzer on six COVID-19 patients at NYU Medical Center had been published in the prestigious Journal of Critical Care. Daxor's prospective multi-center trial has completed enrollment and results are expected to be published shortly. In addition, 10 new studies during 2021 were published in peer-reviewed journals or presented at juried conferences including data presented at the Society for Critical Care Medicine, the Heart Failure Society of America, The American Heart Association meeting, and publication in the Journal of the American College of Cardiology.

08:09 EST Radius Health files sNDA for TYMLOS in men with osteoporosis - Radius Health provided a business progress and regulatory update. On February 25, 2022, the Company filed a Supplemental New Drug Application with the Food and Drug Administration for TYMLOS subcutaneous injection in men with osteoporosis at high risk for fracture. The sNDA filing will be a 10-month FDA review and is based on data from the Phase 3 ATOM study that was announced on October 18, 2021. The ATOM study met the primary endpoint of change in lumbar spine bone mineral density at 12 months compared to placebo as well as secondary endpoints relating to BMD changes in hip and femoral neck. The Company plans to present the full data set from the ATOM study at the upcoming American Association of Clinical Endocrinology Annual Meeting on May 12-14, 2022.

08:08 EST Crinetics appoints James Hassard as Chief Commercial Officer - Crinetics Pharmaceuticals (CRNX) announced the appointment of James Hassard as chief commercial officer. Prior to joining Crinetics, Jim Hassard was chief commercial officer at Arrowhead Pharmaceuticals (ARWR) where he began building the company's commercial capabilities and launch strategy for three rare disease programs.

08:07 EST Candel Therapeutics announces $25M non-dilutive debt financing agreement - Candel Therapeutics announced that it has entered into a loan and security agreement with Silicon Valley Bank for $25 million, $20 million of which will be available immediately. An additional $5 million may be made available in the future if certain conditions and milestones are met. The loan agreement requires monthly payments of interest only for 24 months, after which the principal is repayable in 24 monthly payments. This financing extends the Company's cash runway into the fourth quarter of 2023.

08:06 EST Seritage Growth Properties chair Edward Lampert retires - The company also provided an update with respect to its board of trustees. Edward Lampert, chair of the Seritage board, is retiring from the board effective immediately. In addition, David Fawer and Thomas Steinberg have informed the company that they do not intend to seek reelection to the board at Seritage's 2022 annual shareholder meeting in order to focus on other professional obligations. The board is conducting a search to identify additional board candidates who would further enhance the Board's investment and transaction experience.

08:04 EST BioCardia receives No Objection Letter from Health Canada for CardiAMP trial - BioCardia announced that it has received a No Objection Letter from Health Canada, the country's health services agency, allowing the CardiAMP Heart Failure Trial to expand into Canada. The Phase III pivotal trial is currently enrolling patients in the U.S. Four world-class Canadian clinical sites are currently working through the activation process in order to be ready to begin enrolling patients in the near future. The Company expects to announce these sites in the coming months. The CardiAMP Cell Therapy Heart Failure Trial is evaluating the effectiveness of the CardiAMP Cell Therapy System for improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for New York Heart Association Class II and III patients who have heart failure associated with ischemic cardiomyopathy.

08:03 EST Aqua Metals produces first lithium from spent batteries - Aqua Metals has achieved a key milestone and potentially an important industry breakthrough by producing its first lithium hydroxide from lithium-ion battery black mass at the Company's Innovation Center in the Tahoe-Reno Industrial Center. Currently, the only commercially proven recycling technology being utilized for lithium-ion batteries is smelting which does not recover the lithium. Lithium is a critical component of the lithium-ion batteries that battery manufacturers need to produce to meet the demand of the fast-growing electric vehicle and overall energy storage markets. In addition to producing lithium through a patent-pending proprietary process, the Company's R&D program at the Innovation Center is working to recycle the other key elements of lithium-ion batteries such as cobalt, nickel, copper, and manganese.

08:03 EST Bragg Gaming approved for license in the Bahamas - Bragg Gaming announced that it has been approved for a license to supply its content and services in the Bahamas marking the company's newest regulated market entry. Having completed the certification process, Bragg's Bahamian operator partners will soon be able to offer Bragg's exclusive online casino game titles from proprietary and third-party game development studios.

08:02 EST Flyht receives TSX Venture Exchange approval for CrossConsense acquisition - FLYHT Aerospace Solutions announced that it has received approval from the TSX Venture Exchange for the proposed acquisition of CrossConsense. The arms' length acquisition of CrossConsense is expected to accelerate FLYHT's strategic roadmap to build out a maintenance capability, and will fulfill the Company's goal to increase its presence in the European and Middle East markets. Under terms of the agreement, previously announced on January 27, 2022, FLYHT will acquire all of the outstanding securities of CrossConsense for CAD$1,250,000 in cash and 1,900,000 common shares of FLYHT. The shares will be held in escrow and will be released equally in one-third increments at 4, 16 and 28 months following issuance on the transaction's closing date. Finders' fees of CAD$100,000 will be paid to a third party in connection with the closing of the transaction. This agreement is to be effective January 1, 2022. The parties anticipate closing the transaction as soon as possible after final approval has been received from the German government.

07:58 EST GSK reports EMA accepts marketing authorization application for daprodustat - GlaxoSmithKline announced that the European Medicines Agency, or EMA, validated the marketing authorization application for daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of patients with anaemia of chronic kidney disease, or CKD. "Daprodustat is currently approved in Japan as Duvroq for patients with renal anaemia. The submission to the EMA is the first major regulatory milestone since the approval of Duvroq in Japan in 2020. Regulatory filings are anticipated to continue throughout 2022 with health authorities worldwide," GSK said.

07:55 EST Ardelyx discloses 'going concern' risk language in regulatory filing - In a regulatory filing, Ardelyx said that "Although our financial statements have been prepared on a going concern basis, our current level of cash and investments alone is not sufficient to meet our operating plans for the next twelve months, raising substantial doubt regarding our ability to continue as a going concern. We will require substantial additional financing to achieve our goals, including our goals of commercializing IBSRELA beginning in April 2022 and pursuing a formal dispute resolution process in response to the CRL received from the FDA relating to our NDA for tenapanor for the Hyperphosphatemia Indication and the inability to access necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our efforts to commercialize IBSRELA or to seek and obtain tenapanor for the Hyperphosphatemia Indication."

07:55 EST Energy Transfer buys 51% stake in Energy Transfer Canada, at $1.3B in valuation - Energy Transfer announced the signing of a definitive agreement to sell its 51% interest in Energy Transfer Canada ULC to a joint venture which includes participation by Pembina Pipeline Corporation and global infrastructure funds managed by KKR at a valuation of approximately C$1.6B or US$1.3B including debt and preferred equity. The sale is expected to result in cash proceeds to Energy Transfer of approximately C$340M or US$270M, subject to certain purchase price adjustments. The transaction is expected to close by the third quarter of 2022. Energy Transfer Canada, based in Calgary, is one of Alberta's largest licensed gas processors. Its assets include six natural gas processing plants that have a combined operating capacity of 1,290 million cubic feet per day and a network of approximately 848 miles of natural gas gathering and transportation infrastructure in the Western Canadian Sedimentary Basin. The agreement allows Energy Transfer to divest its high-quality Canadian assets at an attractive valuation to further deleverage its balance sheet and redeploy capital within its U.S. footprint.

07:52 EST Chart Industries receives FNTP for Venture Global's Plaquemines project - Chart Industries (GTLS) has received full notice to proceed, FNTP, for the production of cold boxes and brazed aluminum heat exchangers for Venture Global's 10 MTPA Plaquemines Phase 1 liquefied natural gas export terminal project. In conjunction with the FNTP, Chart booked the full equipment order of $136M for the Plaquemines project from Baker Hughes (BKR). Chart will begin recognizing revenue on this project in 2022 with a multi-year staggered delivery schedule.

07:50 EST Extendicare enters agreements with Revera, Axium - Extendicare announced that it has entered into agreements with Revera and its affiliates and Axium Infrastructure Inc. and its affiliates. Extendicare has entered into agreements with Revera to acquire a 15% managed interest in 18 "class A" long-term care homes located in Ontario and six homes in Manitoba. The remaining 85% interest will continue to be owned by an affiliate of Axium. Relatedly, on closing of the Acquisition, Extendicare will enter into management contracts with Revera to manage all of Revera's other long-term care homes, which comprise 31 "class C" homes located in Ontario and one personal care home located in Manitoba. In addition to the Revera Transactions, Extendicare announced that it has entered into an agreement with Axium in respect of the formation of a joint venture with Axium to jointly redevelop certain of Extendicare's existing Ontario "class C" homes. Axium will own an 85% interest in the joint venture with Extendicare retaining a 15% interest. Extendicare will continue to undertake all development activities in respect of the joint venture homes and will operate the homes upon completion of construction. The Revera transactions will add 56 long-term care homes to the 108 long-term care homes Extendicare currently operates. These homes will also join the SGP Purchasing Partner Network, bringing the total participating beds to over 100,000. The aggregate cash consideration for the Revera Transactions is approximately $36M plus the assumption of approximately $34M in debt, subject to customary adjustments. Certain of the associated debt will be refinanced or repaid on or before closing, resulting in changes in the allocation between cash consideration and debt assumption. The purchase price is expected to be funded from cash on hand.

07:48 EST Installed Building Products acquires Pisgah Insulation and Fireplaces of NC - Installed Building Products announced the acquisition of Pisgah Insulation and Fireplaces of NC Established in 2001, Pisgah is headquartered in Mills River, North Carolina and primarily installs spray foam insulation, fiberglass insulation, and fireplaces into new residential homes in the Asheville, NC market. "With approximately $8.5 million of annual revenue, Pisgah expands our presence in North Carolina," stated Jeff Edwards, Chairman and Chief Executive Officer. Acquisitions remain a key component of our growth strategy and we continue to have a robust pipeline of opportunities across multiple geographies, products, and end markets. On behalf of everyone at Installed Building Products, I would like to welcome Pisgah onto our team."

07:48 EST VersaBank names Garry Clement as Chief Anti-Money Laundering Officer - VersaBank announced it has appointed financial crime prevention expert and advocate, Garry W. G. Clement, to the position of Chief Anti-Money Laundering Officer. Clement is an internationally recognized expert in the areas of money laundering, white-collar crime, organized crime and detection of suspicious activity, including cyber-crime. He brings to VersaBank more than 40 years of policing and financial crime prevention experience, including three decades with the Royal Canadian Mounted Police, culminating in his role as National Director, Proceeds of Crime. In this capacity, Clement was a Canadian representative at Financial Action Task Force, the global money laundering and terrorist financing watchdog, and was a recognized international trainer focused on money laundering investigations. In 2018 Clement was named the Global Fraud and White Collar Advisor of the year.

07:43 EST Cronos Group announces planned exit of Peace Naturals Campus in Ontario - Following a careful evaluation of the Company's global supply chain, the Company has announced the planned exit of its Peace Naturals Campus in Stayner, Ontario, Canada. Cronos Group will continue to operate the Peace Naturals Campus with a phased reduction and transition of activities with a planned exit by the end of 2022. Various research and development initiatives, inclusive of cannabinoid formulation, product development, tissue culture and micropropagation will continue across multiple facilities available to Cronos Group. Continuing to optimize and maintain an agile supply chain is a core element of Cronos Group's strategy. Importantly, Cronos Group has focused on building joint ventures and partnerships around the world with best-in-class operators, such as Cronos GrowCo the Company's joint venture with leading Canadian large-scale greenhouse operators. As GrowCo has developed its capabilities, it has become an important component of the Company's biomass supply. Cronos Group looks forward to leveraging GrowCo's capabilities in premium flower cultivation and efficient downstream processing, with the intention to improve profitability of the Company's Canadian operations. Cronos Group intends to obtain a sales license from Health Canada at GrowCo's facility to maintain the Company's customer relationships and ability to continue supplying the Canadian market. In addition to further leveraging its joint venture with GrowCo, Cronos Group will continue to maintain a network of third-party licensed producers to supplement its cultivation and manufacturing needs. As a result of the Company's planned exit from the Peace Naturals Campus, the Company has incurred a $119.9 million non-cash impairment charge on long-lived assets in the fourth quarter of 2021. In addition, the Company expects to incur charges of approximately $4.5 million in connection with the planned exit, all of which impact the ROW segment. These charges include employee-related costs, such as severance, relocation and other termination benefits, as well as contract termination and other related costs, which are expected to be incurred primarily in the second half of 2022. In addition, the Company anticipates capital expenditures of approximately $2.5 million to modernize information technology systems and build distribution capabilities.

07:42 EST Alliance Data announces new 200,000 share repurchase program - Alliance Data Systems announced that its board of directors has approved a new plan to repurchase up to 200,000 shares of the Company's common stock. The share buyback is designed to offset the dilution associated with restricted stock units expected to vest this year. "This repurchase program reflects Alliance Data's continued commitment to our stated capital priorities, which now include offsetting dilution associated with the annual vesting of outstanding equity awards," said Alliance Data Chief Financial Officer Perry Beberman. The board's authorization permits the Company to make open market share repurchases from time to time through February 28, 2023 in compliance with SEC Rule 10b-18 and subject to market conditions and other factors, including legal and regulatory restrictions and required approvals, up to the aggregate amount authorized by the board. The repurchase program does not obligate the Company to acquire any specific number of shares and may be suspended or terminated at any time.

07:41 EST DarioHealth trading halted, news pending

07:40 EST Osino Resources announces discovery of new high-grade shoot at THW - Osino Resources provides an update of drill assay results for the resource definition drilling recently completed at Twin Hills West, THW. Dave Underwood, Osino's VP Exploration commented: "We took a decision at the beginning of the year to push the drilling along at THW so that we could include it in the next resource update expected during the second quarter. The latest assays show that the southwestern lobe is consistently above 1g/t and 20-40m in drilled width. The lobe of better mineralization is about 300m in strike length and plunges shallowly to the east. It was a welcome surprise when our furthest east hole drilled to close off the mineralization came back with one of our best THW intercepts to date with 30m @ 1.20g/t, likely the start of a new mineralized shoot. The very high-grade feeder zone of 7m @ 7.94 g/t intercepted in the northern step-out at Oryx Central was an additional very pleasant surprise. Future drilling could identify additional gold mineralization at THW." The latest results confirm that the southwestern part of the Oryx lobe at THW is consistent in width and grade and has a strike length of approximately 300m so far, open to the east and west. Drilling also intersected a previously unknown shoot of mineralization on the eastern edge of the Oryx lobe as well as a very high-grade feeder zone in the central Oryx lobe.

07:37 EST Shift4 Payments announces two acquisitions to expand international payments - Shift4 announced that it will acquire both Finaro, a cross-border eCommerce payments provider with a large European presence, and The Giving Block, which specializes in cryptocurrency fundraising for nonprofits. These acquisitions support Shift4's ambitious goals and better position the company to pursue a multi-trillion-dollar addressable market across the world, including accelerating growth in eCommerce, gaming, stadiums, restaurants, hospitality, specialty retail, charitable giving, and a new capability with cryptocurrency enablement. "These two acquisitions build on the momentum from our recent investor day and underscore our aggressive efforts to deliver a unified commerce experience across the world. These deals clearly show our ability to support existing transformational and global customers like SpaceX Starlink & St. Jude Children's Research Hospital and provide a real right-to-win additional customers across the nonprofit vertical. It also represents an exciting and responsible step towards further embracing cryptocurrencies and blockchain technology," said Shift4 CEO Jared Isaacman.

07:36 EST TG Therapeutics expects cash to fund planned operations into 2023 - Cash, cash equivalents and investment securities were $350.3 million as of December 31, 2021, which the Company believes will be sufficient to fund the Company's planned operations into 2023.

07:36 EST Macau reports February casino revenue up 6.1% to 7.76B patacas - Macau's gaming bureau reported February gross revenue from games of fortune in the region was up 6.1% year-over-year to 7.759B patacas. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO). Reference Link

07:31 EST Enveric Biosciences files patent applications for tryptamine-based molecules - Enveric Biosciences announces that it has filed its 10th Patent Cooperation Treaty patent application directed to tryptamine-based derivative molecules, completing the company's broad series of PCT applications covering this family of compounds.

07:31 EST Bitfarms mines 298 bitcoin in January - Bitfarms provided a Bitcoin production and mining operations update for February 2022. "Nearing the opening of our two new farms in Sherbrooke, Quebec, we remain on track to achieving our goal of 3 exahash per second by the end of the first quarter 2022," said Emiliano Grodzki, CEO of Bitfarms. Mining Production: 2.3 EH/s online; 298 new BTC mined during February 2022, up 67% from February 2021; 10.6 BTC mined daily on average in February; 283 BTC from mining deposited into custody in February; 4,883 BTC in custody on February 28, 2022, representing a total value of approximately $210 million based on a BTC price of $43,000. Mining operations: 7,400 new Bitcoin miners capable of 740 PH have been received in February or are in transit. Currently finalizing the first 12 MW capacity at The Bunker site in Sherbrooke, which will immediately make operational over 3,000 new miners and add over 300 PH/s to Bitfarms' online hashrate. Neared completion of the first 16 MW capacity at the Leger site in Sherbrooke, which is scheduled to be online in a few weeks. When operational, Leger will immediately utilize over 4,000 new miners and add more than 400 PH/s to Bitfarms' online hashrate. 2,000 used Bitcoin miners moved or are in transit to the company's Paraguay farm where they are being efficiently redeployed to add an additional 100 PH/s.

07:29 EST Victoria Gold announces results from Dublin Gulch exploration program - Victoria Gold is pleased to provide assay results received to date from the 2021 Dublin Gulch exploration program Lynx diamond drillholes. Lynx is a newly developing on/near-surface gold target within the Dublin Gulch Gold Camp. During the 2021 season, over 20,000 meters of diamond drilling were completed across the claim package; including 11 holes for 2,706 m drilling at Lynx combined with a suite of surface trenches, mapping and soils geochemical surveys. Highlighted assay results received from the first 6 Lynx holes follow: 2.00 g/t Au over 32.3m in LX21-025C; 1.14 g/t Au over 31.4m in LX21-026C; 2.52 g/t Au over 10.2m in LX21-027C; 3.42 g/t Au over 18.3m in LX21-026C. "Lynx is another example of how under explored the Dublin Gulch claim block is." commented John McConnell, President and CEO of Victoria. "Now that Eagle is operating, our team has turned its attention to the systematic exploration of the numerous targets on the block. We fully expect more discoveries in the future." Exploration in 2021 at Lynx expanded upon the initial 2020 work which consisted of 4 diamond drillholes that totaled 594m. The 2021 exploration program was designed to extend the known near-surface gold mineralization and target the vertical extents of gold mineralization. This work culminated in 11 diamond drillholes totaling 2,706 meters in Lynx and 22 surface trenches totalling 2,362 meters.

07:27 EST Alnylam announces FDA acceptance of lumasiran sNDA - Alnylam announced that the FDA has accepted the company's supplemental New Drug Application, or sNDA, for lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1, or HAO1, the gene encoding glycolate oxidase, for the reduction of plasma oxalate in the treatment of patients with advanced primary hyperoxaluria type 1. The FDA has set an action date of October 6, under the Prescription Drug User Fee Act.

07:26 EST Lantronix announces software build for Open-Q 8250CS SOM - Lantronix announced a new software build for its Open-Q 8250CS System on Module. Designed to extend intelligent video capabilities, the software enables the Open-Q 8250CS to deliver a powerful platform for products that need to effectively collect, connect, compute, comprehend and control information. Designed with solid software building blocks, the new development software improves the Open-Q 8250CS SOM by empowering users to get to market quickly with solutions for intelligent IoT vertical markets. It is particularly useful in video collaboration, surveillance, Smart Cities, fleet management, smart display and AI retail boxes by enhancing video processing functionality and reducing latency.

07:25 EST PetVivo to exhibit at Western Veterinary Conference - PetVivo Holdings announced it will be exhibiting at the Western Veterinary Conference to be held March 6th to March 9th, 2022 at the Mandalay Bay Convention Center in Las Vegas, Nevada. PetVivo intends to introduce its lead product, SPRYNG with OsteoCushion Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles, which performs in the joint as wet, slippery micro-cushions used in the management of lameness and other joint related afflictions, such as osteoarthritis. WVC is the largest veterinary conference that services the western part of the United States, and normally plays host to more than 15,000+ participants including many of the top industry professionals.

07:23 EST Bioventus receives FDA clearance for StimRouter Pain Management Device - Bioventus announced that the US Food and Drug Administration, FDA, has awarded 510(k) clearance to the next generation StimRouter Neuromodulation System for the treatment of chronic pain of peripheral nerve origin, excluding craniofacial pain. StimRouter is a minimally invasive neuromodulation medical device consisting of a thin, implanted lead with conductive electrode, external electric field conductor, E-EFC, and StimRouter Plus Mobile Application. "The impact of chronic, debilitating pain is more than just managing the impacted anatomy, it is also about helping return the individual back to a life pre-pain," said John Nosenzo, Chief Commercial Officer, Bioventus. "The emotional and psychological damage from living with pain is horrific and we are pleased to support all the physicians who are committed to improving patient lives, in particular with alternatives to opioids when possible. The next generation StimRouter will support patients and physicians to meet their pain treatment goals as the previous generation of peripheral nerve stimulation has done for many years."

07:22 EST Computer Task Group partners with VCU Health System - CTG announced the successful collaboration with VCU Health System during their Epic go-live in December 2021. Throughout the engagement, CTG provided solutions for legacy applications, critical go-live readiness activities, end-user training, workflow optimization, and in-person end-user application support for the VCU Health enterprise. On December 1, 2021, VCU Health announced its plans for enterprise-wide deployment of Epic, an electronic health record, to provide patient-centered care and a fully connected network across the enterprise by improving patient and clinician communications and care decisions. Early in the organization's Epic implementation planning process, CTG was engaged to support critical legacy applications to allow internal health system resources to focus on Epic planning and application training. VCU Health then engaged CTG for activation and training support solutions. In preparation for the activation, CTG collaborated with the health system on activities related to training, virtual and onsite support levels and logistics, and inpatient and ambulatory technical readiness-all critical to ensuring adequate training, staffing, and technical preparation for go-live.

07:21 EST DarioHealth enters strategic agreement with Sanofi - DarioHealth (DRIO) announced it has entered into a strategic agreement with Sanofi (SNY). The multi-year, $30M agreement, which is subject to certain contingencies, will help accelerate commercial adoption of Dario's full suite of digital therapeutics and drive the expansion of digital health solutions on the Dario platform. Dario and Sanofi will collaborate on promoting the Dario multi-condition digital therapeutics solution, significantly increasing Dario's sales reach in the health plan market and selectively in the employer channel. In addition, the agreement calls for Dario and Sanofi to develop new or enhanced solutions leveraging the Dario platform, and for the parties to generate robust evidence to support future commercialization in the health plan channel. Sanofi selected Dario to leverage its broad suite of digital therapeutics and its ability to engage patients for favorable clinical and financial outcomes, as the solution of choice for its U.S. commercial clients. Dario's single platform helps patients manage diabetes, hypertension, weight management, musculoskeletal and behavioral health, offering Sanofi managed care clients an attractive, easily scalable digital health solution that creates immediate access across a wide range of needs.

07:20 EST Business First Bancshares completes acquisition of Texas Citizens Bancorp - Business First Bancshares, the holding company for b1BANK, has completed its acquisition of Texas Citizens Bancorp, and its wholly owned bank subsidiary, Texas Citizens Bank, National Association. The acquisition became effective March 1, 2022, in accordance with the terms of the previously announced agreement. Upon the completion of the acquisition, b1BANK has approximately $5.3B in assets, $3.6B in loans and $4.6B in deposits. With the addition of the six Texas Citizens banking locations in the Houston market, b1BANK will have 48 full-service Banking Centers and three Loan Production Offices across Louisiana and in the Dallas and Houston markets. Duncan Stewart, Texas Citizens chairman and CEO, will join b1BANK serving as chairman, Houston region. Texas Citizens President Mike Cornett will also join the b1BANK team as vice chair, Houston. Current b1BANK Executive Vice President, Director of Market Expansion Don Hingle will relocate to Houston as regional president, Houston.

07:18 EST The Digital IF Interoperability Consortium announces seven new members - The Digital IF Interoperability Consortium announced the addition of seven new members, in February 2022, from across industry sectors, including: AvL Technologies delivers mobile satellite antenna systems and positioners with the innovative designs, technical superiority, and reliable performance. Calian Advanced Technologies delivers a wide variety of innovative solutions to meet advanced technology, health, learning IT and Cyber needs. Datapath, Inc. is a leading mission critical solutions and services provider in the satellite, C61SR, and commercial communications industries. Integrasys specializes on engineering and manufacturing satellite spectrum monitoring systems in the telecommunications and broadcasting markets. Orbital Research manufactures high-performance frequency converters and RF components for the satellite communications industry. PdM WESS manages the acquisition, development and modernization of enterprise satellite communications systems and state-of-the-art satellite network control and planning systems for use with the defense satellite communications systems, as well as wideband global satellite and commercial satellite systems. Swedish Space Corporation is a leading global provider of advanced space services and a full-service supplier of state-of-the-art space engineering satellite and launch services to commercial and institutional customers worldwide.

07:14 EST OneWater Marine announces acquisition of YakGear - OneWater Marine announced that its subsidiary, T-H Marine, has acquired YakGear, a supplier of kayak equipment, paddle sports accessories, and boat mounting accessories based in Houston, Texas. YakGear will continue to operate as a standalone division of T-H Marine at its current facility in Houston, Texas. "The OneWater family looks forward to welcoming the YakGear team as we continue to diversify our suite of aftermarket marine products. YakGear is T-H Marine's second acquisition of 2022, underscoring the ability of T-H Marine's acquisition engine to add horsepower to OneWater's business model, aftermarket diversification, and growth strategy. Between T-H Marine's leading omni-channel presence in the marine industry and YakGear's position in the world of kayaking and paddle sports, we believe the combined forces are poised for further success." said Austin Singleton, Chief Executive Officer for OneWater.

07:12 EST Achilles Therapeutics announces 2022 key upcoming milestones - Patient Dosing: Dose first patients with higher dose cNeT monotherapy and cNeT in combination with a PD-1 inhibitor in 2Q 2022. Higher-dose Monotherapy: Report additional patient data from higher-dose cohort of cNeT monotherapy for the treatment of NSCLC and melanoma in 2H 2022. cNeT Combination: Report initial patient data from cNeT in combination with a PD-1 inhibitor for the treatment of melanoma in 2H 2022. Manufacturing Expansion: Increase manufacturing capacity in the United Kingdom with GMP licensure of the Cell & Gene Therapy Catapult facility in 2Q 2022. Tumor Archiving Program: Initiate program in 1H 2022

07:10 EST Rhythm Pharmaceuticals expects cash to fund requirements into 2H23 - Based on its current operating plans, Rhythm expects that its existing cash, cash equivalents and short-term investments as of December 31, 2021 will be sufficient to fund its operating expenses and capital expenditure requirements into at least the second half of 2023.

07:09 EST Kohl's announces $3B share repurchase program - Kohl's board of directors approved a $3B share repurchase authorization and the company plans to repurchase at least $1B in shares in 2022, of which $500M is expected to be repurchased through open market transactions or an ASR program executed in Q2.

07:04 EST Wendy's approves new $100M share repurchase plan - The company's Board of Directors has approved a new $100M share repurchase authorization, expiring in February 2023.

07:03 EST Wendy's reports Q4 U.S. systemwide sales (0.7%) - Reports Q4 International systemwide sales growth 13.5%; Global 0.8%.

07:01 EST Wendy's reports Q4 U.S. same-restaurant sales growth 6.1% - Reports Q4 International same-restaurant sales growth of 18.1%; Global 7.3%.

06:58 EST NexGen Energy uplists to NYSE from NYSE American - NexGen Energy announced that it has been approved for uplisting on the New York Stock Exchange from its current listing on the NYSE American. The company's common stock will begin trading under the symbol "NXE" at the opening of trading on March 4.

06:57 EST CGI Inc. intends to repurchase 3.97M shares held by CPQ for C$100.80 per share - CGI announced that it intends to enter into a private agreement with Caisse de depot et placement du Quebec, or CDPQ, for the purchase for cancellation of 3,968,159 of its Class A subordinate voting shares held by CDPQ for a price of C$100.80 per Class A Share, which represents a discount to the closing price on February 28, 2022 of the Class A Shares on the Toronto Stock Exchange. The transaction will be made in connection with the periodic portfolio rebalancing of CDPQ. Once completed, CDPQ will continue to hold approximately 23.5M Class A Shares, representing approximately 9.8% of CGI's total outstanding shares.

06:53 EST Xenia Hotels to acquire W Nashville for $328.7M - Xenia Hotels announced it has agreed to acquire the 346-key W Nashville for a purchase price of $328.7M or $950,000 per key. The Company expects to close the transaction by the end of the first quarter and fund the acquisition with available cash. The completion of the transaction is subject to customary closing conditions.

06:50 EST Pfizer announces results from Phase 3 CLOVER trial of C. difficile vaccine - Pfizer announced results from the CLOVER trial, a pivotal Phase 3 study evaluating its Clostridioides difficile vaccine candidate in the prevention of C. difficile infection. Initial analyses of two protocol defined secondary endpoints indicated a highly favorable benefit in reducing CDI severity and 100% vaccine efficacy in preventing medically attended CDI, although the trial did not meet its pre-specified primary endpoint of prevention of primary CDI. Safety reviews indicated that the investigational vaccine was safe and well tolerated. Clostridioides difficile infection is a serious infection associated with diarrhea that may progress to severe and debilitating illness with potentially fatal outcomes and the United States Centers for Disease Control and Prevention has classified CDI as an urgent public health threat.3 Close to 10 percent of patients aged 65 or older with a healthcare-associated C. difficile infection are at risk of death within 30 days of diagnosis and constitute 90 percent of those with risk for fatal outcome. All laboratory-confirmed CDI cases are among persons with diarrhea who seek medical care and have a stool specimen collected and tested for C. difficile. In 2017, the incidence of medically attended laboratory-confirmed CDI cases in those age 50 and older and those age 65 and older was 286/100,000 persons and 452/100,000 persons, respectively. CLOVER enrolled approximately 17,500 adults, 50 years and older. The study was expected to accrue 66 cases of CDI within two years of the primary vaccination series. Due to significant operational challenges created in part by the COVID-19 pandemic, the final analysis was performed at 42 cases within four years after agreement from the U.S. Food and Drug Administration to amend the protocol. The two primary efficacy endpoints in CLOVER were first primary episode of CDI greater than or equal to14 days following completion of the third dose and first primary episode of CDI greater than or equal to14 days following completion of the second dose. Vaccine efficacy under the primary endpoint was 31% following the third dose and 28.6% following the second dose for the C. difficile vaccine candidate. For all CDI cases recorded 14 days post dose 3, vaccine efficacy 49%, 47% and 31% up to 12 months, 24 months and at final analysis, respectively. The vaccine was very well tolerated and showed a favorable safety profile. Local and systemic reactions were mild to moderate, with mostly pain at the injection site with higher incidence after the second and third doses. The number of participants reporting overall adverse events, serious AEs, withdrawals and deaths were similar between the two groups. A highly favorable potential benefit was noted in reducing the duration and severity of disease. The pre-specified secondary endpoint of the proportion of participants who sought medical attention for CDI showed a 0-11 case split, corresponding to 100% vaccine efficacy. None of the participants with CDI in the vaccine group required medical attention compared to 11 in the placebo group. In addition, the median CDI duration was 1 versus 4 days and the mean duration was 3 versus 16 days comparing vaccine to placebo, corresponding to a 75% and 80% reduction in disease episode, respectively, in vaccinated people. Pfizer will further evaluate data from the trial and determine next steps for the C. difficile vaccine program. The company plans to submit for presentation of the Phase 3 CLOVER trial results, including all secondary endpoints, at a future medical congress and for publication in a peer-reviewed scientific journal.

06:45 EST Xenia Hotels sees FY22 capital expenditures $95M - Sees FY22 interest expense $77M.

06:37 EST AstraZeneca's Alexion, Neurimmune close collaboration deal for NI006 - The company states: "Alexion, AstraZeneca's Rare Disease group, has closed an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, an underdiagnosed, systemic condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Alexion has been granted an exclusive worldwide licence to develop, manufacture and commercialise NI006. Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is $30M. Alexion will make additional contingent milestone payments of up to $730m upon achievement of certain development, regulatory and commercial milestones. It will also pay low-to-mid teen royalties on net sales of any approved medicine resulting from the collaboration. Neurimmune will continue to be responsible for completion of the current Phase Ib clinical trial on behalf of Alexion, and Alexion will pay certain trial costs. Alexion will be responsible for further clinical development, manufacturing and commercialisation following the Phase Ib trial." Reference Link

06:36 EST Microsoft removing RT apps, banning Russia state-owned ads - Microsoft reviewed areas it is aiding Ukraine. Protection from cyberattacks: "In recent days, we have provided threat intelligence and defensive suggestions to Ukrainian officials regarding attacks on a range of targets," the company said. Protection from state-sponsored disinformation: In accordance with the EU's recent decision, the Microsoft Start platform will not display any state-sponsored RT and Sputnik content. Microsoft is removing RT news apps from its Windows app store and further de-ranking these sites' search results on Bing so that it will only return RT and Sputnik links when a user clearly intends to navigate to those pages. Finally, Microsoft is banning all advertisements from RT and Sputnik across our ad network and will not place any ads from our ad network on these sites. Support for humanitarian aid: Microsoft Philanthropies and UN Affairs teams work closely with the International Committee of the Red Cross, ICRC, and multiple UN agencies. Our initial and immediate focus has been on support for humanitarian organizations that are doing work to help support refugees fleeing into neighboring countries. Reference Link

06:22 EST Molson Coors' Coors Light eliminates 6-pack plastic rings globally - Coors Light announced it will eliminate plastic rings from packaging globally, where Molson Coors owns brewing operations, and is set to become the largest beer brand in North America to move away from plastic rings. To support the move to more sustainable packaging, Molson Coors Beverage Company will invest $85M enabling Coors Light to begin the transition to fully recyclable and sustainably sourced cardboard-wrap carriers later this year.

06:16 EST BrightView acquires TDE Group, terms not disclosed - BrightView Holdings announced the acquisition of TDE Group, a snow removal and commercial landscaping company headquartered in suburban Detroit with operations in Windsor, Ontario. Terms of the transaction were not disclosed. TDE Group is the 34th firm to be purchased by BrightView under its successful long-term acquisition growth strategy.

06:13 EST JinkoSolar provides update on dialogue with UN Global Compact Liaison Office - JinkoSolar recently hosted a dialogue with delegates from the UN Global Compact Liaison Office in Beijing, on the role of solar PV technology development in achieving global Sustainable Development Goals, or SDGs, set up by the United Nations. The dialogue was attended by Meng Liu, Head of Liaison Office of the UN Global Compact, and Kangping Chen, CEO of Jinko Solar, the principal operating subsidiary of JinkoSolar. The company said, "Mr. Chen briefly introduced how JinkoSolar's advanced technology enhances the penetration of solar PV application, accelerates global energy transition, and brings about effective, scalable, and sustainable change. Ms. Liu welcomed JinkoSolar's participation in the United Nations Global Compact since last year and JinkoSolar's commitment to the ten principles of the Global Compact. She provided positive feedback on the important role JinkoSolar has played to accelerate the shift towards renewables, enhancing the accessibility of green and clean energy in underdeveloped regions and complimented the Company's efforts to support the acceleration of the achievement of the Sustainable Development Goals in this regard. Topics under discussion touched upon JinkoSolar's best practices on advancing renewable investment in the Belt and Road countries, promoting innovative solar plus solutions to assist regions lacking reliable electricity and clean water, forming new partnerships, and staying committed to bridging the energy inequality gap."

06:04 EST Toshiba names Taro Shimada to succeed Satoshi Tsunakawa as CEO - Toshiba CEO Satoshi Tsunakawa has stepped down and Chief Digital Officer Taro Shimada will succeed him, the company said on Tuesday. Shimada will lead the company that will run the energy and infrastructure business after the spinoff, Toshiba added.

05:43 EST Caravelle expects to list on Nasdaq via Pacifico Acquisition pact - Caravelle, a global carbon-neutral ocean-going technology company, has signed a letter of intent with Pacifico Acquisition Corp. Caravelle will be expected to be listed on Nasdaq. At the same time, a number of private equity funds participated in PIPE. The founder and CEO, Zhang Guohua, has more than 20 years of experience in the entire industry chain of the wood industry.

05:37 EST CNH Industrial CEO Scott Wine purchases 150,000 shares at $13.69 average - The company also announced that Scott Wine, CEO, CNH Industrial, has purchased 150,000 of the company's common shares at an average price of $13.69. This transaction has been duly notified to the regulatory authorities. Wine holds in total 350,000 of the company's common shares.

05:34 EST Vaalco Energy provides update on Etame field reconfiguration - Vaalco provided an update on the Etame field reconfiguration in conjunction with the replacement of the existing Floating Production, Storage and Offloading unit, or FPSO, with a Floating Storage and Offloading vessel, or FSO, offshore Gabon. Vaalco anticipates that all of the associated engineering, long-lead equipment and significant contracts are proceeding in-line with the project timelines and expected delivery schedules for the deployment of the FSO in Q3. Field reconfiguration activities are expected to begin in March, as planned. The Cap Diamant, a double-hull crude tanker built in 2001 that is being re-engineered as the new FSO, arrived at a shipyard in Bahrain in late February on schedule, for the final modifications and certifications. Vaalco expects the vessel will begin sea trials in late June before being mobilized to Gabon. Compared to the current FPSO agreement, the new FSO will reduce storage and offloading costs by almost 50%, increase effective capacity for storage by over 50%, and is expected to lead to an extension of the economic field life, resulting in a corresponding increase in recovery and reserves at Etame. Current total field level capital conversion estimates are $40M to $50M gross. This capital investment is projected to save approximately $20M to $25M gross per year in operational costs through 2030, giving the project a payback period of less than two and a half years.

05:28 EST Ozon comments on impact of sanctions on its operations - Ozon informed that Ozon Holdings is not subject to any sanctions at the moment. Ozon also notes that there are no regulatory restrictions on the ability of U.S. persons to acquire and trade in Ozon's securities, and non-U.S. persons are not exposed to any U.S. secondary sanctions risks in connection with such transactions. The company said, "Based on the currently available information, the Company's management believes that there is no direct material adverse effect of the U.S., EU and other sanctions recently imposed on Russia on our current day-to-day e-commerce platform's operations and our ability to conduct business. We primarily operate in Russia, and over 95% of GMV incl. services is generated in Russia. Over 90% of our buyers and sellers are also located in Russia. Both sellers and buyers can continue to supply and purchase goods through Ozon's e-commerce platform as usual. All of Ozon's key IT systems, as well as key physical infrastructure, including fulfillment centers, sorting hubs, dark stores and first and last-mile operations are fully functional, and there have been no interruptions to either IT or logistics processes resulting from sanctions. Transacting on our e-commerce platform continues without any disruptions resulting from sanctions. We continue to process payments of our customers and pay our sellers in the regular way. Customers are able to place prepaid orders using Mastercard, Visa, Mir, etc. on our platform. Prepaid orders account for over 90% of orders. Ozon is able to use SWIFT with a select number of partner banks. We have a strong liquidity position with approximately 80% foreign exchange liquidity, which serves as a natural foreign exchange hedge for the Company and believe we have sufficient ruble liquidity for our current day-to-day operations. We have ensured that we have access to our cash, cash equivalents and deposits, and the majority of our deposits is now held in Russia. The Company had cash, cash equivalents and short-term bank deposits of RUB 126 billion as of December 31, 2021. The Company notes that on February 25, 2022, Ozon filed a request to the Office of Foreign Assets Control ("OFAC") of the U.S. Treasury Department to remove Limited Liability Company Ozon Bank ("Ozon Bank") from the Specially Designated Nationals and Blocked Persons List (the "SDN List") since Ozon Bank is not linked to Sovcombank. As per our recent press release "Ozon Informs about Developments at Ozon Bank", on February 24, 2022, Ozon's banking subsidiary, Ozon Bank, was included in the SDN List by OFAC as an entity "linked to Sovcombank Open Joint Stock Company". Ozon acquired 100% of share capital of Oney Bank LLC (now Ozon Bank) from Sovcombank on May 26, 2021, when Oney Bank ceased to be an affiliate of the Sovcombank. Ozon can provide no assurance of the outcome and timing of the OFAC resolution on Ozon's application. Our business is likely, however, to be indirectly impacted by the U.S., EU and other sanctions recently imposed on Russia, particularly if they have a continued impact on the Russian economy, which could, among other things, have a material impact on activity on our platform. We may also face greater difficulties raising capital in the future, which could potentially reduce the level of future investment into infrastructure expansion and operations. We also cannot provide any assurance that any further development in sanctions, or escalation of the Ukraine situation more generally, will not have a significant impact on our business, financial condition or results of operations. In these challenging times, we remain focused on supporting all of our stakeholders, including customers, merchants, our multiple various business partners, employees and investors to the best of our ability. Ozon expects to release its full-year 2021 financial results on April 5, 2022, where we will also provide an update on the key year-to-date trends."

05:23 EST NIO delivers 6,131 vehicles in February, up 9.9% - Nio announced its February delivery results. Nio delivered 6,131 vehicles in February, representing an increase of 9.9% year-over-year. The deliveries consisted of 1,084 ES8s, the company's six- or seven-seater premium smart electric SUV, 3,309 ES6s, the company's five-seater high-performance premium smart electric SUV, and 1,738 EC6s, the company's five-seater premium smart electric coupe SUV. As of February 28, cumulative deliveries of the ES8, ES6 and EC6 reached 182,853 vehicles. During the production suspension of the Nio-JAC manufacturing plant in the Spring Festival holiday from January 31 to February 6, the Company adjusted the production lines to prepare for the delivery of ET7 in March. On February 28, the company received a letter of in-principle approval from the Stock Exchange of Hong Kong Limited for the secondary listing of its Class A ordinary shares by way of introduction on the Main Board of the SEHK with the trading expected to commence on March 10.

05:19 EST Hutchmed receives approval to market fruquintinib in Macau region - Hutchmed announced that it has received approval to market fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors, or VEGFR, 1, 2 and 3, in the Macau Special Administrative Region. The approval follows the latest update to the provisions on new drug importation which allows drugs that have been approved in one or more specified jurisdictions to be authorized for use in Macau.

05:09 EST XPeng reports February deliveries of 6,225 vehicles, up 180% - XPeng announced its vehicle delivery results for February. XPeng delivered 6,225 Smart EVs in February, representing a 180% increase year-over-year. The February deliveries consisted of 3,537 P7 smart sports sedans, representing a 151% year-over-year increase. A total of 2,059 P5 smart family sedans were delivered in February, bringing cumulative deliveries of the P5 to 13,953 since its launch in September 2021. Also 629 G3 & G3i smart compact SUVs were delivered in February. The technology upgrade at the Zhaoqing plant during the Chinese New Year holiday from late January to early February has been completed. Production at the Zhaoqing plant resumed in mid-February as planned. The upgrade enables the company to accelerate delivery of its significant order backlog in hand.